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Abstract 
The quest for genes associated with different phenotypes and diseases is a central theme of research 
in human genetics. Several human phenotypes/diseases including height, myopia, diabetes, and 
others show complex pattern of inheritance where many genes together with environmental factors 
influence the intensity of a phenotype or disease. The genome-wide association study (GWAS) has 
been successful in mapping loci associated to variety of human traits and diseases. GWAS test for 
association of single nucleotide polymorphism (SNP) markers with a phenotype of interest at the 
genome-wide scale, this hence requires a severe multiple testing correction for statistical 
significance (p-value < 5 × 10
-8
). A single marker association approach has limited power in finding 
disease susceptibility genes especially in situations where the risk architecture of a gene is defined 
by many SNPs rather than one or two. This issue can be addressed through gene-based association 
approaches where the combined (or mean) statistics of a number of markers in a gene is tested for 
association with the trait of interest. Gene-based association approaches are established as a 
complementary approach to GWAS.  
It is well established that genes work in concert as molecular networks and cellular pathways to 
perform biological processes. Individual tests for association of a gene (or a SNP in a gene) with 
phenotype may have limited power in identifying interacting genes with small effects. SNP or gene-
based tests are limited in how much they can reveal of the biological mechanism behind phenotypic 
variation. Pathway-based association approaches, where gene-based tests statistics are combined 
into gene sets and tested for association, have been developed to overcome these limitations. Each 
gene set represents a biological pathway or a process, based on prior biological knowledge. Various 
techniques have been proposed to perform pathway-based association tests on GWAS data, 
including ALIGATOR, MAGENTA, and INRICH. These packages show several limitations, which 
can be addressed by the development of a new pathway-based association approach. 
The aim of this thesis is to demonstrate the analytical approaches (GWAS and post-GWAS) to 
identify genes and pathways associated with complex ophthalmology traits and report methods for 
gene- and pathways-based analysis of GWAS summary data. Chapter 1 introduces the basic 
principles and strategies involved in GWAS analysis. Further, it extensively reviews the popular 
methods available for gene-based and pathway-based association tests.  
Chapter 2 describes an initial GWAS on corneal curvature, a phenotype of interest to diseases such 
as myopia and keratoconus, in Australians and further meta-analysis of two cohorts comprising of 
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1788 Australian twins and their families and 1013 individuals from a birth cohort from Western 
Australia. It also reports on replication in Australians of Northern European ancestry of the 
previously reported association of SNPs in PDGFRA and FRAP1 genes with corneal curvature in an 
Asian population.  
Chapter 3 is a demonstration of GWAS and pathway-based analysis. It reports the first GWAS and 
meta-analysis for corneal astigmatism in two Australian cohort studies, total sample size ~2,700. 
This chapter describes the application of Pathway-VEGAS, an extension of the gene-based analysis 
tool Versatile Gene-based Association Study (VEGAS) program for pathway-based analysis. 
Chapter 4 reports the successful application of VEGAS and Pathway-VEGAS to GWAS meta-
analysis data. As part of the international glaucoma genetics consortium (IGGC), I participated in 
genetic analysis of the vertical cup disc ratio (VCDR) phenotype. This manuscript describes the 
meta-analysis of GWAS on a discovery sample of 21,094 individuals from ten cohorts of northern 
European ancestry and a replication sample of 6,784 individuals from four Asian cohorts. Gene-
based and pathway-based tests were performed using the VEGAS and Pathway-VEGAS programs 
separately for northern European ancestry samples and Asian ancestry samples, and respective 
results were meta-analysed. This chapter demonstrates the advantages of using different approaches 
such as single marker GWAS, gene-based association approach and pathway based association 
approach. 
Chapter 5 presents the VEGAS2 software. VEGAS is one of the most popular gene-based 
association software. VEGAS however has some limitations such as the inability to perform a gene-
based tests on the X chromosome, dependence on HapMap2 data to model the correlation between 
SNPs and inflexibility in the selection of gene boundary. The VEGAS2 software is an extension of 
VEGAS, redeveloped and upgraded to overcome these limitations. 
Chapter 6 presents the VEGAS2Pathway approach for pathway analysis of GWAS summary data. 
This chapter describes the shortcomings of many popular pathway-based association approaches, 
and how VEGAS2-Pathway overcomes these limitations. Further it demonstrates the application of 
VEGAS2Pathway on the endometriosis GWAS summary data. 
The last chapter provides the contributions this thesis makes to the literature and discusses its 
implications, limitations and future directions. In conclusion, my thesis provides the methodological 
and analytical approaches to further our knowledge in human genetics.  
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Chapter 1 Introduction 
1.1 Genetic Mapping of Human Phenotypes 
The quest for gene mapping for various traits dates back to the time when Principles of Mendelian 
Genetics were first established. Mendel stated two principles, firstly, each offspring receives one of 
two alleles of a genetic factor in equal proportion from their mother and father; this law is called as 
the Law of Segregation. Alleles are two or more versions of a genetic factor at particular genetic 
locus. The second law Mendel proposed is popularly known as the Law of Inheritance that states 
inheritance (transfer of genetic factor from one generation to the next) of one genetic factor, is 
independent of all other genes. Prior to the establishment of Mendel’s principles of inheritance, the 
study of heredity traits was based on the, now discarded, postulate of blending, where the traits 
were inherited from parents and mixed.  
Since the genetic understanding of different phenotypic traits was in its infancy, Mendel’s 
principles led to the formation of two groups of quantitative geneticists. These were the Mendelians, 
who concentrated on traits following single gene patterns of inheritance known as Mendelian traits 
(e.g., pea shape) and the Biometricians who considered normally distributed quantitative traits (e.g., 
seed weight, height). The biometric traits are now more generally referred to as common or 
complex traits. Complex traits are caused by the combination of multiple genetic and environmental 
factors
1
. Typically these traits have polygenic origin where a large number of small effect size 
variants play a part in variation of a phenotype
2
. 
The milestone paper by R. A. Fisher titled “The correlation between relative on the supposition of 
Mendelian Inheritance” brought these two worlds of genetics together3. Fisher3 reported that the 
genetics of complex traits could be explained by Mendelian patterns of inheritance if many genes 
together affect the trait. Fisher’s report3 provided a basis for the development of strategies to map 
genes that regulate the variation in the phenotypic trait of interest. The variation of a phenotype can 
be decomposed into genetic and environmental components. The heritability of a trait is defined as 
the proportion of the phenotypic variation explained by the genetic component
4
. Genetic component 
can further be partitioned into additive effects (variation due to heterozygotes is intermediate 
between that of the homozygotes) and non-additive effects (dominant or recessive, gene-gene 
interaction etc.). Most commonly for complex traits, the genetic component of the additive effect is 
used to define heritability (also known as narrow sense heritability). 
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Gene-mapping strategies aim to map the genetic component underlying the variation in a 
phenotype. These strategies are based on the way in which recombination events (breaking and 
joining of DNA molecule to make new molecule of DNA during meiosis) occur across genome. 
The likelihood of transfer of two genetic loci together from one generation to the next depends on 
the rate of recombination events between them. Loci close to each other are less likely to be 
separated by recombination events than those farther away. A haplotype is a block of set of alleles 
on a small segment of chromosome that tend to transmit together through a pedigree. Linkage 
disequilibrium (LD) is the term to define the non-random association of the alleles at nearby loci 
reflecting haplotypes descended from a common ancestor
5; 6
. 
Linkage studies test whether a causal locus for a phenotype and a genetic marker are linked (close 
to each other). Linkage approaches for gene mapping are broadly divided into two categories 
parametric and non-parametric. A typical parametric approach requires specification of a set of 
parameters. These comprise the frequency of the disease allele, the mode of inheritance (e.g. 
dominant, recessive) and the penetrance of each genotype (proportion of individuals with a 
particular genotype that develop the disease)
7
. The frequencies of alleles at each marker are also 
required although this may be estimated from the available data. Based on these parameters one can 
construct a likelihood function that models the coinheritance of each chromosomal position with a 
phenotype. For each position along the genome one can compute lod scores, which is the logarithm 
of the ratio of likelihoods that a marker and causal loci are linked verses not linked. The relevant 
parameters can be specified for a Mendelian trait, but for a complex phenotype this approach is less 
tractable. Non-parametric approaches such as those originally derived for the affected sib pair 
(ASP) design were developed to perform linkage analysis on complex traits. Because such non-
parametric approaches do not explicitly model the mode of inheritance of the trait, such approaches 
have been labelled model-free. Before describing the non-parametric test using ASPs, it is 
important to understand the two terminologies identity by state (IBS) and identity by descent (IBD). 
IBS is a term used to describe two identical alleles or segments of chromosome, whereas IBD 
suggests identical alleles are descended from common ancestor. If an allele is shared between a pair 
of sibs, the shared allele will be IBS but may not necessarily IBD. The ASP approach is based on 
the principle that the IBD sharing between affected sibs at a disease locus is higher than would be 
expected at a randomly selected locus
7
. 
Both parametric and non-parametric linkage approaches for gene mapping require a pedigree. An 
alternative method for gene mapping is association analysis. Such methods can use either pedigree 
or population data for gene mapping. Unlike linkage approaches that test for a specific genetic 
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relationship between a disease locus and a genetic marker, association approaches are based on the 
strength of correlation between a marker allele and variation in a phenotype
8
. The transmission 
disequilibrium test (TDT)
9; 10
 is one of the approaches developed for association tests. It needs 
family data with one or more affected offspring; the parents’ disease status is irrelevant but only 
heterozygous parents for the genetic marker tested are informative. Then to test the null hypothesis, 
H0 = no association between a marker and a disease, one calculates the ratio of square of the 
difference between number of parents transferred one allele over the other allele versus the total 
number of parents. Association testing on unrelated individuals is typically performed using 
contingency table test or regression models (refer section 1.4 for GWAS approaches). 
1.2 Association versus Linkage Approach for Gene Mapping of 
Complex Traits 
In 1996, Risch and Merikangas
11
 compared the sample size requirement for ASP and TDT based 
approaches to reject the null hypothesis. They calculated the sample size required to attain power 1-
β to distinguish the genotypic relative risk γ (an increased chance of having disease to an individual 
with particular genotype) from the null hypothesis of no effect at significance threshold α using the 
following formula
11
 
(𝑍𝛼 −  𝜎 𝑍1 − 𝛽)
2
𝜇2
⁄  
Where Z is the standard normal deviate, σ and μ2 are mean and variance of the distribution of a 
phenotype. They considered the multiplicative genetic risk model
12
. As explained previously, ASP 
tests the chromosomal regions where the IBD sharing of haplotypes between affected siblings 
differs from the expected value. Using following formula Risch and Merikangas
11
 (1996) calculated 
the expected proportion Y of allele shared between affected siblings for a closely linked marker 
locus that is fully informative (heterozygosity = 1) 
𝑌 =
(1 + 𝑤)
(2 + 𝑤)⁄  
Where 𝑤 =
[𝑝𝑞(𝛾 − 1)2]
(𝑝𝛾 + 𝑞)⁄ , p and q are allele frequencies. 
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As mentioned in previous section, one of the conditions for TDT test is that the parents should be 
heterozygous for the causal locus. Using the same model mentioned for ASP test, the probability of 
a parent of affected pair of siblings to be heterozygous for an allele is
11
 
ℎ =  
𝑝𝑞(𝛾 + 1)2
2(𝑝𝛾 + 𝑞)2 +  𝑝𝑞(𝛾 − 1)2
⁄  
Then probability of a heterozygous parent transferring a risk allele to the affected child
11
 
𝑃(𝑡𝑟𝑎𝑛𝑠𝑓𝑒𝑟 𝑜𝑓 𝑟𝑖𝑠𝑘 𝑎𝑙𝑙𝑒𝑙𝑒) =  
𝛾
(1 +  𝛾)⁄  
For linkage analysis, a lod score above 3 suggest a marker is linked with causal loci with 5% chance 
of being false positive
13
. lod score threshold 3 corresponds to type 1 error probability α = 10-4. For α 
= 10
-4
, the normal deviate Zα = 3.72. Risch and Merikangas
11
 (1996) assumed there are 100,000 
genes across human genome each with 5 diallelic polymorphisms, suggesting 1,000,000 
independent association tests (tests for 10 alleles of 100,000 genes). The 5% false positive rate can 
be obtained for 1,000,000 independent association tests across the human genome with significance 
threshold α = 5 × 10-8; hence the normal deviate Zα = 5.33. 
Using these formulas, Risch and Merikangas
11
 (1996) calculated the sample size needed to achieve 
80% power to identify a risk allele at different combinations of genotypic relative risk and allele 
frequency. They show that the association (TDT) approach requires manageable sample size (in 
hundreds or thousands) to detect a locus conferring genotypic relative risk less than 2. However, to 
detect a locus with a similar genotypic relative risk linkage (ASP) requires an unfeasibly large 
sample (hundreds of thousands). 
Sham et al.
14
 provided a further comparison of the power of linkage and association studies. Under 
the variance component model proposed by Fulker et al.,
15
 Sham et al.
14
 performed an association 
and linkage analysis on sib-ship samples. They identified that the power of association at a given 
locus is directly proportional to the risk locus heritability and the power of linkage is proportional to 
the square of the risk locus heritability. Hence, the power of association becomes progressively 
higher than that of linkage as the variation explained by the risk locus decreases. Although it was 
quite clear the association approaches are well powered to map genes responsible for variation in 
complex traits, aspects of this study are now out of date. For example, this study was limited in that 
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it was based on now obsolete annotations of the different functional units and variants in the human 
genome. 
1.3 Human Genome, HapMap and the 1000 Genomes Project 
The human genome project (HGP) was initiated in 1990 and completed in 2003. This project 
yielded comprehensive information about the architecture of the human genome. The draft 
sequence of HGP, released in 2001
16; 17
, was limited due to incomplete coverage of euchromatic 
regions
18
. The second draft sequence with ~99% coverage of the euchromatin portion of the human 
genome was released as Build 35 in 2004
18
. The progress to obtain highly accurate human genome 
sequence is continuing with latest release as Build 38 (release date: December 24, 2013). 
As highlighted by Risch and Merichangas in 1996
11
, and Sham et al. in 2000
14
 (section 1.1), 
association is a powerful test for detecting genetic variation associated with a complex phenotype. 
An incomplete catalogue of human genome variation and the high cost of sequencing made whole 
genome association tests unfeasible. The indirect association approaches were proposed
19; 20
, where 
a set of markers (tag SNPs) is identified such that it can represent the variation in whole genome. 
The HapMap project was initiated in 2002 with aim to develop a haplotype map of the human 
genome
21
. The phase 1 HapMap data was released in 2005. It provided information on more than 
one million SNPs through sequencing of 269 individuals from four populations. In 2007 the 
HapMap phase 2 release characterised 3.1 million SNPs genotyped in 270 individuals from four 
populations
22
. The HapMap phase 3 release (2010) genotyped 1.6 million SNPs in 11 global 
populations
23
. 
In 2008, the 1000 Genomes Project was announced
24
. It aimed to sequence at least one thousand 
individuals from around the world to create a more detailed catalogue of human genetic variation
24
. 
In addition to common variants, the 1000 Genomes Project was designed to detail the variants with 
minor allele frequency (MAF) below 0.05 and report structural variants (deletions and insertions). 
The phase 1 data of the 1000 Genomes Project was released in 2012, reporting ~38 million SNPs, 
~1.4 million insertions and deletions and ~14,000 larger deletions from sequencing of 1092 
individuals from 14 populations
25
. Low coverage (4-6x) whole genome sequencing, high coverage 
(80x) exome sequencing and dense genotyping data was used to identify variants in human genome. 
To improve the genotype accuracy of the low coverage data, statistically phased genotypes were 
derived using LD information from sequencing projects and HapMap phase 3 reference data
26
. 
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1.4 Genome-wide Association Studies 
The HapMap and the 1000 Genomes resources characterised the haplotype map of human 
populations with different ancestries. The HapMap project estimated that a subset of 500,000 to 
1,000,000 SNPs can represent the 80% of the genetic variation in populations of European 
ancestry
27
. During this period microarray technology was developed to enable large-scale 
genotyping
28; 29
. From this, genome-wide association study (GWAS) was developed such that the 
samples were genotyped for thousands of tag SNPs that capture variation in most of the genome. 
GWAS was initially founded on the common disease common variant hypothesis
30; 31
. This 
hypothesis argues that the variation in common phenotypes is attributable to the number of variants 
(with low penetrance) that are common in a population. Yang et al.
32
 reported that the 45% of the 
variation in height is traceable from 294,831 common variants (MAF > 0.01). Whilst other variants 
(such as rare SNPs, structural variants) are also been explored extensively for association with 
common diseases
33-38
, this thesis focuses on the analysis of common variants. 
Traditionally association studies were developed as a follow-up study for linkage analysis. These 
were hypothesis driven candidate gene studies to locate a gene associated with a trait in a 
chromosomal region reported to be linked with a phenotype of interest
39
. Unlike hypothesis driven 
candidate gene association tests, GWAS is a hypothesis free approach that tests the association 
between thousands of markers and variation in a phenotype. The GWAS approach can be applied 
on discrete or quantitative phenotypes. Linear regression or Spearman's rank correlation tests are 
generally used to perform an analysis on quantitative traits. For discrete phenotypes logistic 
regression tests or contingency table-based tests are commonly used. For family data, a popular test 
is a score test, which improves the power of family-based GWAS by estimating missing genotypes 
through pedigree information
40
. 
GWAS is a straightforward approach but the results can be confounded by population 
stratification
13
 (subgroups of individuals with ancestry differences may represent genetically 
distinct subsets) or due to batch effect
41; 42
 (for example due to cases and controls being genotyped 
on separate platforms). Population stratification can be corrected by filtering individuals based on 
eigenvalues from principal component analysis or adjusting population substructure covariates (or 
both), or through mixed model regression analysis
43-45
. If unadjusted for, substructure can lead to 
inflated test statistics. Such genomic inflation is commonly assessed by computing λ, the ratio of 
median of χ2 test statistics versus the median under null across all markers in a GWAS. 
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In a GWAS, hundreds of thousands or millions of SNPs undergo association testing. Since SNPs 
are in LD (non-independent), a Bonferroni correction for all genotyped SNPs would be an 
inappropriate method to determine a multiple testing threshold. Dudbridge and Gusnanto
46
 proposed 
7.2 × 10
-8
 as the genome-wide significance threshold through permutation of sub-sampled 
genotypes at increasing densities. Pe’er et al.47 reported the need for multiple testing corrections of 
500,000 independent tests in Europeans and 1,000,000 tests in Africans. Following these reports 5 × 
10
-8
 is widely used as the genome-wide significance threshold in GWAS analysis
48
. 
A GWAS is typically performed in two-stages: discovery and replication stage. To control false 
positive findings in discovery stage, SNPs identified associated with a trait are replicated in an 
independent study
49
. It has been reported that the joint analysis (meta-analysis of samples) gives 
better power to find associated loci compared to the two-stage analysis
50
 (where loci are selected 
based on a strict p-value < 5 × 10
-8
 threshold in the first stage and then tested at less stringent 
significant threshold (0.05/number of follow-up SNPs) in the smaller set of samples which 
comprise the second stage). Several software packages have implemented approaches to perform 
the meta-analysis such as METAL
51
 and PLINK
52
. Such software only requires summary files with 
the association test statistics from the included studies. In practice the included studies may perform 
their genotyping using a range of microarray chips that each captures a different set of markers to 
represent haplotypes in human genome. Imputing all genome-wide SNPs from these tag SNPs, 
based on the haplotype information provided by the HapMap and the 1000 Genomes resources, can 
improve the comparison across different arrays and GWAS studies. By improving the density of 
SNPs in a region, imputation facilitates a better-powered joint analysis. Imputation can also help in 
further characterization of an associated region by allowing the mapping of the causal variant(s). 
Fine mapping the association signal down to biologically more plausible SNPs in the region may 
help inform downstream functional studies which seek to understand how the implicated variant 
affects gene and protein function. 
1.5 Application of GWAS in Ophthalmology 
In this thesis, the GWAS approach is used to study eye disease and hence I review here the 
literature on the GWAS approach applied to ophthalmologic traits. Amongst the very first 
successful GWASs on human phenotypes were those in the eye disease age-related macular 
degeneration
53; 54
 (AMD). Other early studies were those of oesophageal cancer
55
, cardiac 
repolarization
56
 and inflammatory bowel disease
57
 first reported in 2005 and 2006. Following these 
early successes using small sample sizes, a landmark paper in complex traits generally was the 
Welcome Trust Case Control Consortium’s (WTCCC) paper titled “Genome-wide association study 
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of 14,000 cases of seven common diseases and 3,000 shared controls”, in 200758. The WTCCC 
paper arguably marked the true beginning of the GWAS era. This was followed by an exponential 
increase in GWAS publications. Figure 1 shows the trend of increase in publications in GWAS 
from 2005 to 2012, taken from NHGRI GWAS catalogue
59
. 
Figure 1.1 Trend of GWAS reports in period 2005-2012. The figure is taken from The 
NHGRI GWAS Catalog 59, Credit: Teri Manolio 
As noted above, one of the first success stories of GWAS was the discovery of an association 
between variants in the CFH gene and AMD
53; 60; 61
. Further significant associations of CFB and C2 
established the role of complement system in AMD
62
. Clinical studies targeting the complement 
pathway for treatment or prevention of AMD treatment have shown promising results
63
. GWAS 
paved the way for understanding of ~50% of the heritability of AMD
64
. GWAS on other heritable 
ophthalmological diseases including glaucoma and keratoconus have also been reported. 
Glaucoma is recognised as a optic neuropathy in which at least one eye show both structural 
changes in optic nerve head and vision loss
65
. Primary open angle glaucoma (POAG) is one of the 
most common types of glaucoma. In 2009 Nakano et al.,
66
 published the first GWAS on POAG in a 
Japanese population. This paper reports moderate but not genome-wide significant association (p-
value < 5 × 10
-8
) of variants in ZP4, PLXDC2 and DKFZp762A217 (TMTC2) genes, these findings 
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failed to replicate in an independent Indian population. The rs4236601 SNP close to CAV1 and 
CAV2 genes was the first genome-wide significant hit reported to be associated with POAG by 
Thorleifsson et al.
67
 They replicated the association of rs4236601 in European and Chinese cohorts. 
The allele frequency of rs4236601 is variable across ancestries (MAF in different HapMap 
populations: 0.45 in Yoruba, 0.28 in Utah CEPH (Utah residents with ancestry from northern and 
western Europe) population, 0.02 in Han Chinese and monomorphic in Japanese). The A allele of 
rs4236601 showed much higher risk in the Chinese cohort than that in the Europeans
67
. Also 
Thorleifsson et al.,
67
 observed that A allele of rs4236601 show higher risk in normal-pressure 
(Intraocular pressure (IOP) ≤ 21 mmHg) glaucoma cases. Burdon et al.,68 reported association of 
variants TMOC1 and the CDKN2B-AS1 genes with advanced open angle glaucoma. This study 
failed to replicate the association of rs4236601 in CAV1/CAV2 even though Thorleifsson et al.
67
 
used some of the cases included in this study in their replication sample. As mentioned earlier, 
rs4236601 is monomorphic in the Japanese population. While considering other SNPs that are 
polymorphic in Japanese populations Osman et al.
69
 showed association of SNPs in CAV1/CAV2 in 
Japanese cohort (top SNP rs7795356; p-value = 0.0073). A GWAS on non-advanced POAG 
implicated association of variants in SIX1 and 8q22 regions
70
. Recently ABCA1, AFAP1, GMDS and 
PMM2 have been reported as associated with POAG
71; 72
. 
POAG is a group of heterogeneous diseases, characterised by clinical parameters such as intraocular 
pressure (IOP), corneal curvature thickness (CCT) and morphological changes in optic nerve 
head
73
. The optic nerve head is an oval structure with a central depression called a cup. The vertical 
cup disc ratio (VCDR) is typically measured to assess the degree of nerve damage in glaucoma 
patients. VCDR, IOP and CCT are highly heritable quantitative traits
74
. Understanding the genetic 
basis of variation in these quantitative traits will allow better characterisation of POAG patients. 
Before the work on this thesis started, 8 loci were reported as associated with VCDR
75; 76
. Amongst 
these 8 were 3 loci (CDKN2B, ATOH7 and SIX1) implicated in POAG. 
Keratoconus is an ophthalmology disease characterised by the progressive thinning of cornea over 
time
77
. Two early GWASs on keratoconus did not find significant associations
77; 78
. Lu et al.
79
 
reported two variants associated with CCT in the genes FOXO1 and FNDC3B, which confer large 
risks for keratoconus (with genome-wide significant association). These SNPs were further 
replicated in an independent keratoconus GWAS with 157 cases and 673 controls
80
. Another 
quantitative phenotype with clinically relevance for keratoconus is corneal curvature. Progressive 
steepening of cornea is observed in follow-up studies of keratoconus patients
81
. Prior to this thesis 
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there was only one GWAS on corneal curvature, with that study reporting the association of FRAP1 
and PDGFRA genes in Asians
82
. 
Corneal astigmatism is another cornea related condition. It is characterised by inaccurate focusing 
of light at a single point in the eye due to refractive abnormalities or irregularities in the cornea. 
Before start of my PhD, only one GWAS was published reporting association of PDGFRA with 
corneal astigmatism in the Asians
83
. 
Recently Chandra et al.
64
 reviewed applications of GWAS in ophthalmology. They discussed 
number of challenges in conducting and analysing GWAS findings in terms of need for large 
sample size, false–positive results, lack of knowledge of gene function, biases due to genotyping 
errors and case-control selection. They strongly advocated the need for independent replication of 
GWAS findings. They also highlighted the use of quantitative traits such as optic nerve parameters 
(VCDR, cup area, rim area, and disc area), CCT, corneal curvature, intraocular pressure and 
spherical equivalent to understand the disease aetiology. The first two result chapters of my thesis 
describe the independent replications of associations reported for corneal curvature and corneal 
astigmatism respectively, in the Australian cohorts. Moreover, the third result chapter reports a 
large-scale meta-analysis on VCDR, and calculates the aggregate effect of VCDR-associated loci 
on POAG risk. 
1.6 Building on per-SNP Association Studies 
1.6.1 Gene-Based Testing 
Early GWASs focused on testing each SNP separately for association with a trait of interest. Gene 
based association approaches were subsequently developed that test the association of the combined 
effect of all SNPs within a gene with the variation of a phenotype while accounting for between 
SNP LD. In my thesis I build upon early approaches to gene-based testing. Identifying the 
biological mechanisms underlying complex phenotypes is the ultimate goal of GWAS
84
. Identifying 
genes associated with a phenotype is the crucial step in this direction. In a typical GWAS 
publication, genetic variation explained by a region is represented by the most significantly 
associated SNP. Yang et al.
85
 reported a gene could have several independent SNPs each with a 
significant effect on a phenotype. If each independent variant shows an effect in only a subset of 
samples in a study then the single marker association approach will be underpowered to identify an 
associated gene. The association test for combined effects of many SNPs in a functional unit such 
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as a gene is hence potentially a more powerful approach than per-SNP GWAS to identify a gene 
associated with a phenotype. 
The LD between SNPs can inflate the aggregated test statistics. The simplest approach to calculate 
gene-based test statistics while accounting for the LD between SNPs is the permutation approach 
implemented in PLINK 1.07
52
. In this approach, the observed summed χ2 test statistics is 
benchmarked against the summed χ2 test statistics generated through permuting case/control status 
or the phenotypic value (for quantitative trait) while keeping markers intact to maintain the LD. 
This approach is considered the gold standard for gene-based analysis, but its application in practice 
is subjected to number of limitations. Firstly, this approach is computationally demanding. 
Secondly, it requires genotype data to perform gene-based analysis. As mentioned previously to 
attain greater power for association tests a meta-analysis is often performed. Due to privacy and 
ethical limitations on data sharing and other logistical concerns, a meta-analysis is usually 
performed using summary data. As a result, the permutation approach can generally not be used to 
perform gene-based analysis using meta-analysis data. Thirdly, this approach can only be applied in 
a population based GWAS. It cannot be used in other popular GWAS methods such as family-based 
GWAS and DNA-pooling based GWAS. 
The VEGAS approach was developed as an alternative to the permutation method for gene-based 
analysis. It compares the observed summed χ2 test statistics for a gene against sum of square of 
normal variates generated through the simulation of a multivariate normal distribution with mean 0 
and variance Σ, a n ×n matrix of LD (r). VEGAS overcome the mentioned limitations of the 
permutation approach and gives similar empirical gene association test statistics. Another popular 
approach for gene-based analysis is GATES, which uses the extended Simes procedure to calculate 
gene-based association p-values
86
. VEGAS joint-SNP gene-based approach is one of the most 
powerful among available gene-based approaches
86; 87
. However, the original implementation of 
VEGAS is limited to using HapMap samples as a reference instead of the more detailed 1000 
Genomes reference data. In chapter 5 we report on the VEGAS2 software as an improvement to the 
VEGAS approach. 
In addition to upgrading the VEGAS approach to use 1000 Genomes data, VEGAS2 was also 
developed to perform gene-based tests on the X chromosome. Traditionally, the majority of 
reported GWASs have focused solely on the autosomes and ignored variants in the sex 
chromosome. Since males have only one copy of the X chromosome, and females have two, it is 
likely X chromosome variants may influence both sex-linked and non-sex-linked traits and diseases. 
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In the early embryonic stage, one of the two copies of X chromosomes in females is either partly or 
fully inactivated (silenced)
88
. These special characteristics of the X chromosome must be modelled 
in association tests
89
. A gene-based test for the X chromosome might help in identifying novel 
genes associated with complex traits. 
The original implementation of VEGAS defines the gene boundary as the coding region plus 50kb 
flanking sequence to incorporate possible regulatory variants. Since this regulatory boundary of a 
gene is arbitrarily defined we developed the VEGAS2 implementation to give the user flexibility to 
define the gene-boundary. 
1.6.2 Pathway-based Testing 
Pathway-based analysis of GWAS data is a strategy that tests the association of combined test 
statistics of variants within a pathway to the phenotype of interest. In pathway analysis, the SNPs’ 
association test statistics with variation in a phenotype are assigned to genes to test the enrichment 
of a biological pathway. Pathway-based approaches have several advantages. The associated 
pathway provides a biological interpretation for the statistically combined GWAS association 
results. Since the associated pathway represents the combined effect of several independent loci, it 
may explain more genetic variation than is observed in per-SNP associations
90
. Genetic 
heterogeneity among different ethnic populations is one of the sources of concern in per-SNP 
GWAS analysis. If different genes and alleles of the same pathway contribute to the associations in 
different ethnicities then the combined effect of a pathway will not show genetic heterogeneity
91
. 
Moreover, pathway analysis can help in prioritizing genomic regions for further characterization. In 
past few years, several strategies for pathway-based analysis of GWAS data have been reported and 
discussed extensively
90; 92-118
. Pathway-based association approaches are subject to several 
confounders discussed in following section. 
1.6.2.1 Points to Consider in Pathway Analysis of GWAS Data 
1.6.2.1.1 Pathway Definition 
The term “pathway” is context dependent. This term has been used to describe a wide range of 
biological processes and gene-sets such as cell functions, metabolic processes, co-expressing genes 
and gene families. Most of the pathway-based strategies require the user to provide a pre-defined 
pathways to test. Pathguide
119
 provides direct links to around 325 different biological pathway 
resources. MSigDB
120
, Gene ontology
121
 (GO), Kyoto Encyclopedia of Genes and Genomes
122
 
(KEGG) and BioCarta are some of the most popular resources of manually and computationally 
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curated pathway resources available. Some specialized pathway databases are also available which 
were curated for specific purposes including MetaCyc for metabolic pathways
123
, TRANSPATH for 
transcriptional regulation
124
. Use of many curated and computationally compiled pathways will 
increase the likelihood of comprehensive coverage while pathway testing, although as discussed 
below, this comes at the expense of an increased multiple testing penalty. 
1.6.2.1.2 Applicability to summary level data 
As the case with gene-based approaches (refer to section 1.6), the sample size available for pathway 
analysis is likely to be maximized if the approach can be applied to summary files generated from 
GWAS. 
1.6.2.1.3 SNP selection 
One of the main purposes of the pathway approach is to identify the loci that individually have 
moderate an effect on a phenotype. Some pathway approaches pre-filter the list of SNPs based on a 
particular per-SNP p-value threshold but in doing so they may be discarding many individually 
moderate effects that taken together may prove to be important. 
1.6.2.1.4 Linkage disequilibrium between SNPs 
LD between SNPs may affect the pathway-based test statistic either by generating an inflated gene 
based test statistics or by over representing the same region of neighbouring or overlapping genes in 
pathway statistic. 
1.6.2.1.5 Gene and pathway length 
Both gene size and pathway size are important issues, which may influence results from a particular 
pathway test. For pathway tests based on gene-based results, if the significance of a gene correlates 
with its size then this needs to be taken into account. Similarly, pathway size should not correlate 
with the significance. If there is a positive correlation between pathway size and p-value then 
significance will be biased towards bigger pathways and vice versa. 
1.6.2.1.6 Testing for multiple overlapping pathways 
A practical issue with some popular pathway definitions is that some pathways have overlapping 
sets of genes and any analysis method should appropriately take this into account. Methods such as 
Bonferroni, Šidák corrections or FDR procedures can be employed to correct for the inflation in 
false positives generated by the large number of independent tests. The pathways obtained from 
different databases may not be independent, with a gene or a set of genes can be represented in 
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several pathways. Applying traditional correction for multiple testing would be inappropriate for 
such non-independent pathways. A successful pathway approach should take into account these 
correlated tests. 
1.6.2.1.7 Usage of software 
While addressing the number of points mentioned earlier, a pathway analysis implementation 
should be user friendly. As mentioned before the pathway analysis should incorporate gene-sets 
from a number of sources, and should not force the user to perform complicated processing of their 
files before analysis. Moreover, the implementation should be computationally manageable for 
thousands of pathways. 
1.6.2.2 Strategies for Pathway Association Approaches 
Based on their definition of the null hypothesis, pathway association strategies are divided into self-
contained and competitive tests. Self-contained methods test the association signal within a pathway 
against no signal, whereas a competitive method tests association of a pathway against all other 
pathways under consideration. Considering the polygenic nature of complex traits, the self-
contained test may reject null hypothesis for more gene-sets than the competitive test
125
 leading to 
high genomic inflation and an increased number of false-positive associations. 
A number of approaches for competitive pathway analysis of GWAS data have been reported. 
Popular ones include GenGen
92
, MAGENTA
117
 (Meta-Analysis Gene-set Enrichment of VariaNT 
Association), ALIGATOR
93
 (Association List Go AnnoTatOR) and INRICH
118
 (INterval 
enRICHment analysis). Based on strategy, these approaches can broadly categorised into gene-set 
enrichment analysis (GSEA) based approaches such as GenGen and MAGENTA (which compare 
the rank score of a pathway against permuted sets) and hyper geometric approaches such as 
ALIGATOR and INRICH (which compare significant versus non-significant genes in a pathway). 
Here, we discuss strategies of some of the most popular approaches (GenGen, ALIGATOR, 
MAGENTA and INRICH) for competitive pathway analysis. Further table 1.1 compares these 
approaches with reference to the previously discussed seven points; pathway definitions, input data, 
SNP selection, LD between SNPs, gene and pathway size, multiple testing and usage. 
1.6.2.2.1 GenGen 
GenGen
92
 was the first approach proposed for pathway-based analysis of GWAS data. It is based on 
the gene-set enrichment analysis (GSEA) algorithm
126
, which is an established pathway-based 
analysis strategy for microarray expression data. 
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GenGen maps all SNPs in a range of 500kb from 5’ and 3’ untranslated regions (UTRs) of a gene 
and assigns the top SNP test statistic as the gene’s test statistics. Further it calculates the weighted 
Kolmogorov-Smirnov-like running-sum statistic for pathway S consisting of NH number of genes to 
identify overrepresentation of genes as follows 
𝐸𝑆(𝑆) =  max
1≤𝑗≤𝑁
{ ∑
|𝑟(𝑗∗)|
𝑝
𝑁𝑅
𝐺𝑗∗∈𝑆,𝑗
∗≤𝑗
−  ∑
1
𝑁 − 𝑁𝐻
𝐺𝑗∗∈𝑆,𝑗
∗≤𝑗
} 
Where, 
𝑁𝑅 =  ∑ |𝑟(𝑗∗)|
𝑝
𝐺𝑗∗  ∈ 𝑆
 
N = Total number of genes (where j = 1… N) 
r = Χ2 test statistics 
p = parameter to give weights to genes depending of their association tests statistics. 
The ES(S) calculation is dependent on the maximum statistic within each gene. GenGen adjusts for 
gene size using the two-step correction procedure. Firstly, it repeatedly calculates enrichment score 
ES(S, π) for π permutations of disease labels. Then calculate the normalised enrichment score (NES) 
using following equation: 
𝑁𝐸𝑆 =  
𝐸𝑆(𝑆) −  𝑚𝑒𝑎𝑛[𝐸𝑆(𝑆, 𝜋)]
𝑆𝐷[𝐸𝑆(𝑆, 𝜋)]
 
GenGen corrects for the multiple hypothesis tests using the permutation approach. 
1.6.2.2.2  ALIGATOR 
ALIGATOR
93
 requires only GWAS summary data. It tests for the overrepresentation of gene 
ontology terms in the list of genes consisting of significantly associated SNPs. 
ALIGATOR identifies the lists of (N) significant genes by preselecting significant SNPs (p-value < 
0.05). SNPs are assigned to genes if they fall within the 20kb of the transcription boundary of a 
gene. Then it generates 5000 replicate gene lists by randomly selecting SNPs from the set of all 
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SNPs used in the study. Using replicate gene lists ALIGATOR calculates the empirical p-value of 
the number of significantly associated genes in each pathway category. Finally using a bootstrap 
approach it corrects for the number of multiple hypotheses tested. 
1.6.2.2.3 MAGENTA 
MAGENTA
117
 was developed to carry out pathway analysis on GWAS meta-analysis summary 
data. This strategy was also inspired by GSEA
126
, as was the case with GenGen
92
.  
MAGENTA maps SNPs to a gene if they range in 110kb of 5’ and 40kb of 3’ of a gene’s 
transcription boundary and uses the top SNP test statistic to define the gene-based test statistic. It 
corrects for confounding factors such as gene size, LD between SNPs within a gene, genetic 
distance per kb and recombination hotspots per kb by step-wise multiple regression procedure. If 
the same SNPs’ test statistic is assigned to two or more neighboring genes from the same pathway 
then only the highest corrected gene score is used to compute the pathway test statistic. Further, 
MAGENTA calculates the empirical p-value of enrichment by comparing the number of significant 
genes (GWAS specific 95
th
 percentile gene p-values) in the observed gene-set verses randomly 
sampled gene-sets. It uses the Bonferroni correction procedure to correct for multiple testing. 
1.6.2.2.4 INRICH 
INRICH
118
 performs gene-set enrichment analysis of GWAS data using LD independent genomic 
interval regions. 
INRICH requires four pre-processed input files including a reference gene file (can be downloaded 
from gene-annotation database such as NCBI
127
, UCSC
128
), a reference SNP file (the reference 
SNPs examined in the association study), a target gene set file (this can be downloaded from 
pathway annotation database such as GO, KEGG) and an associated interval file (which can be 
generated using –clump parameter in PLINK 1.07 but requires reference or original genotype files). 
INRICH merges overlapping genes belonging to a gene-set to avoid genomic inflation due to multi-
counting statistical dependent regions. It also merges the overlapping testing intervals to ensure 
testing units are statistically independent. For a given gene-set INRICH generates the distribution of 
enrichment test statistics of null interval sets by randomly assigning genomic locations that have 
approximately as many overlapping genes and SNPs as of the original interval. Then the empirical 
p-value of association is calculated by comparing test statistics of original gene-set against null 
interval sets. Finally it corrects for the number of multiple hypothesis tests using the permutation 
approach. 
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Table 1.1 Comparison of GenGen, ALIGATOR, MAGENTA and INRICH 
 GenGen ALIGATOR MAGENTA INRICH 
Pathway 
definition 
KEGG, Biocarta 
and GO 
GO KEGG, Panther 
MSigDB and 
GO 
KEGG and GO 
Input data Genotype data Summary data Summary data Summary data 
SNP selection All SNPs User specified 
threshold 
All SNPs p-value < 1 × 
10
-4
 (suggested)
 
 
LD correction Within gene but 
ignores between 
genes 
NO correction Within and 
between genes 
Within and 
between genes 
Gene and 
pathway size 
Corrects  Corrects Corrects Corrects 
Multiple testing Permutation 
procedure 
Bootstrap 
approach 
Bonferroni or 
FDR correction 
Permutation 
procedure 
Usage Command line 
implementation 
Command line 
implementation 
Matlab license 
required 
Command line 
implementation 
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1.6.2.3 Summary of Pathway-based Methods 
The pathway-based approaches mentioned above each make different assumptions, which may 
reduce the power of their association tested or may lead to false positive findings. ALIGATOR
93
 
and INRICH
118
 define significant SNPs by pre-specifying a p-value threshold, before using the list 
of significant SNPs for pathway analysis. As explained previously, pre-filtering SNPs may lead to 
loss of significant information. GenGen
92
 and MAGENTA
117
 use only the top SNP within each 
gene to characterize that gene’s effect. A single gene may have number of independent associations 
and ignoring these SNPs may lead to loss of power. ALIGATOR
93
 calculates gene-based test 
statistics by combining the effects of SNPs within a gene but assumes the LD within genes is 
constant, leading to conservative gene-based p-values in high LD regions. If a pathway contains 
neighbouring genes then MAGENTA
117
 considers only one gene out of all neighbouring genes for 
pathway association test. Discarding neighbouring genes may lead to reduced power. Ideally a 
pathway approach should incorporate as much available information as possible while correctly 
accounting for the correlation between SNPs. 
An ideal pathway approach should be applicable to both family and population data. Since GWAS 
meta-analysis is commonly done using summary data, ideally the approach should work on 
summary data. Also the implementation should be user friendly and computationally efficient. 
In chapter 6, I introduce VEGAS2Pathway approach that uses the association information from all 
SNPs for a complex phenotype and can perform a competitive test while accounting for LD 
between them. We provide a web-based implementation that require only list of SNPs and 
association p-values as an input. 
1.7 Brief Summary and Aims of the Thesis 
This thesis contains some methods development chapters and some data analysis chapters (where 
both the standard and new methods are applied). The data analysis chapters primarily aim to 
identify genetic loci associated with ophthalmology traits (corneal curvature, corneal astigmatism 
and VCDR). 
Chapter 2 is a data analysis chapter, focusing on corneal curvature. This chapter reports the 
replication of variants in FRAP1 and PDGFRA genes in Australian cohort, previously reported 
associated with corneal curvature in Asians. It also reports the first GWAS meta-analysis for 
corneal curvature in a northern European ancestry sample. 
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Chapter 3 aims to replicate the published findings of association of variants in PDGFRA genes with 
corneal astigmatism in Asians, using Australian cohort data. In addition to reporting the first 
GWAS for corneal astigmatism in a northern European ancestry sample, this chapter reports the 
application of VEGAS-Pathway, an in-house software program for pathway-based association 
testing. 
In chapter 4 we report a cross-ancestry meta-analysis on VCDR and risk conferred by associated 
loci on POAG patients. In this chapter we demonstrate the application of gene-based test using 
VEGAS. We performed joint-SNPs gene-based test using VEGAS to identify genes associated with 
VCDR that were not identified through per-SNP GWAS. We further used gene-based association p-
values to identify enriched GO pathway for VCDR using the VEGAS-Pathway approach. 
Chapter 5 reports on the VEGAS2 software for gene-based association tests. The limitations of 
VEGAS outlined previously including inflexibility in the definition of gene boundary, use of only 
the HapMap phase 2 data (rather than 1000 Genomes) and inability to perform gene-based testing 
on X chromosome data. VEGAS2 overcomes these limitations. 
Chapter 6 reports VEGAS2Pathway approach for pathway based association test. This chapter 
discusses the requirement for the ideal pathway association approach, and reports how 
VEGAS2Pathway satisfies most of these expectations. It reports the detailed strategy behind 
VEGAS2Pathway, and further demonstrates its application on GWAS summary data from a case-
control study of endometriosis. Painter et al.
129
 reported the GWAS on endometriosis during the 
first year of my PhD when I conceived the VEGAS2Pathway project. During that time I 
collaborated with Painter et al.
129
 to demonstrate the application of VEGAS2Pathway using 
endometriosis GWAS data. Hence chapter 6 reports application of VEGAS2Pathway on 
endometriosis instead on ophthalmic traits. 
  
20 | P a g e  
 
Chapter 2 Genome wide association study for corneal 
curvature in Australian cohorts of northern European ancestry 
This section is published as: 
Mishra A
*
, Yazar S
*
, Hewitt AW, Mountain JA, Ang W, Pennell CE, Martin NG, Montgomery 
GW, Hammond CJ, Young TL, Macgregor S, Mackey DA. Genetic variants near PDGFRA are 
associated with corneal curvature in Australians. Invest Ophthalmol Vis Sci. 2012 Oct 
11;53(11):7131-6. (doi: 10.1167/iovs.12-10489) 
2.1 Summary and its Impact 
This chapter describes the steps involved in a single marker genome wide association study 
(GWAS) of corneal curvature. The steps include ethical approvals, phenotype measurement, 
genotyping, quality control, power calculation, discovery GWAS, replication, imputation and meta-
analysis. This chapter reports on an initial GWAS on corneal curvature in Australian cohorts of 
northern European ancestry. This work replicates alleles in the FRAP1 and PDGFRA genes, which 
were previously reported associated with corneal curvature in Asian population
82
. 
The cornea is the outermost transparent tissue of an eye. The clarity and curvature of cornea is 
important for correct visual acuity. Figure 2.1 describes the vision process where the light reflected 
from distant object is refracted through cornea and lens to focus on the retina to create an inverted 
image. 
 
Figure 2.1: The vision process (Source: 
http://www.hsc.csu.edu.au/biology/options/communication/2951/CommPart3.html, reproduced 
with permission from NSW HSC Online http://hsc.csu.edu.au© NSW Department of Education and 
Communities, and Charles Stuart University, 2014)  
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The cornea is responsible for 70% of the total refracting (focusing) power of an eye
130
. Hence, small 
variations in the corneal curvature can significantly affect the visual acuity. The heritability of the 
corneal curvature ranges between 60% and 95%, depending on ethnicity, age, stature and 
environmental conditions
82; 131-133
. Irregularities in the cornea are associated with diseases such 
askeratoconus, refractive error and Marfan syndrome, reinforcing the importance of understanding 
the genetics of variation in corneal curvature. This chapter reports the first GWAS on corneal 
curvature in the Australians of northern European ancestry. 
The GWAS was performed using samples from a twin cohort data (Brisbane adolescent twin study, 
BATS and the twin’s eye study in Tasmania, TEST)134 and a population cohort (Raine) with sample 
sizes 1788 and 1013 respectively. The power to detect a variant explaining at least 1% of variation 
in corneal curvature using a combined sample size of 2801 (effective sample size around 2000) at 
type-1 error cut off 5 × 10
-8
 is 30%. In contrast the power for replication of just the two previously 
published SNPs in FRAP1 and PDGFRA (i.e. significance threshold of 0.05/2 = 0.025) is more than 
99%. This chapter reports the replication of association of the alleles in FRAP1 and PDGFRA genes 
with corneal curvature in Australians, previously reported in Asians. 
The major finding of this chapter was the association of PDGFRA with corneal curvature. The 
PDGFRA gene is now one of the most important candidates for molecular characterizations of 
corneal diseases including posterior polymorphous corneal dystrophy
64; 135
. Moreover the initial 
GWAS report helped in further collaboration between Asian and Australian groups to perform cross 
ancestry GWAS meta-analysis on corneal curvature under the consortia for refractive error and 
myopia (CREAM). This cross ancestry meta-analysis project is ongoing. 
2.2 Contribution of Candidate 
I performed GWAS on twin cohort (BATS and TEST) data using Merlin software
136
. I did the 
power analysis using genetic power calculator
137
. I meta-analysed GWAS results from twin cohort 
(BATS and TEST) and population cohort (Raine) studies. I wrote more than 80% of the manuscript 
under supervision of Stuart Macgregor. 
2.3 Contribution of Other Authors 
David Mackey, Stuart Macgregor, Alex Hewitt, Grant Montgomery and Nicholas Martin collected 
samples for BATS and TEST studies, whereas Seyhan Yazar, Alex Hewitt, David Mackey, Jenny 
Mountain, Wei Ang and Craig Pennell collected samples for the Raine study. Seyhan Yazar under 
the supervision of Alex Hewitt and David Mackey contributed in writing the methods section. 
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Stuart Macgregor, Alex Hewitt and David Mackey contributed to the study concept and design. 
Nicholas Martin reviewed the draft manuscript. Stuart Macgregor helped write and edit the 
manuscript. All authors read and approved the manuscript. 
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Supplementary figure 1: 
 
Supplementary Figure 1: Association of variants at the TRIM29 locus: The top SNP rs2444240 
has a P value 3.66 × 10-07. The red shading shows the degree of linkage disequilibrium between 
rs2444240 and neighboring SNPs. This SNP is 31kb upstream to the TRIM29 gene. The light blue 
line displays the rate of recombination with scale on right hand axis.  
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Supplementary table 1:  The 25 most significant SNPs from the meta-analysis 
Marker Name Allele Effect 
Standard 
Error P value 
Chro
moso
me Pos b36 Pos b37 
gene 
(within 
50KB) 
rs2444240 T/G -0.03645 0.007128 3.66 × 10
-07
 11 119545652 120040442 TRIM29 
rs494965 T/C 0.03659 0.007283 4.50 × 10
-07
 11 119558860 120053650 TRIM29 
rs470606 T/G -0.0359 0.007129 5.66 × 10
-07
 11 119533412 120028202 TRIM29 
rs470373 T/C 0.036203 0.007282 5.90 × 10
-07
 11 119531481 120026271 TRIM29 
rs4936509 T/C -0.0335 0.007116 2.82 × 10
-06
 11 119546654 120041444 TRIM29 
rs7146198 A/C 0.047981 0.01044 3.94 × 10
-06
 14 69713922 70644169 SLC8A3 
rs740145 C/G -0.17316 0.036726 4.52 × 10
-06
 7 29888049 29921524 WIPF3 
rs2383876 A/T -0.05078 0.011068 5.25 × 10
-06
 8 74228733 74066179 RPESP 
rs7144262 T/C 0.046798 0.010332 5.37 × 10
-06
 14 69716861 70647108 SLC8A3 
rs2250402 T/G 0.059229 0.01319 6.20 × 10
-06
 15 38109844 40322552 EIF2AK4 
rs1999052 A/G 0.046463 0.010331 6.24 × 10
-06
 14 69716944 70647191 SLC8A3 
rs17093693 T/G 0.046498 0.010348 6.33 × 10
-06
 14 69719545 70649792 SLC8A3 
rs11987235 A/G -0.0384 0.008486 6.93 × 10
-06
 8 117710791 117641610 EIF3H 
rs2693676 A/G -0.04348 0.009627 7.22 × 10
-06
 14 98677233 99607480 BCL11B 
rs1273225 T/C -0.04337 0.00961 7.29 × 10
-06
 14 98678970 99609217 BCL11B 
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rs1273226 T/C 0.043834 0.009813 7.39 × 10
-06
 14 98677595 99607842 BCL11B 
rs2834902 A/C 0.035868 0.008037 7.53 × 10
-06
 21 35610398 36688528 - 
rs807443 A/G -0.04479 0.009968 8.12 × 10
-06
 14 98698257 99628504 BCL11B 
rs2307101 T/C -0.05946 0.013216 8.41 × 10
-06
 15 38109752 40322460 EIF2AK4 
rs1869463 A/G -0.0331 0.00741 8.85 × 10
-06
 4 58999889 59305132 - 
rs2007685 T/C -0.0331 0.00741 8.86 × 10
-06
 4 59004041 59309284 - 
rs17137734 T/C 0.089259 0.020295 9.17 × 10
-06
 15 25090519 27507773 GABRG3 
rs10152133 A/G 0.090063 0.020494 9.31 × 10
-06
 15 25093268 27510522 GABRG3 
rs10152135 T/G 0.090027 0.020494 9.35 × 10
-06
 15 25093283 27510537 GABRG3 
rs10152293 A/C -0.08786 0.019567 9.59 × 10
-06
 15 25093096 27510350 GABRG3 
*The first letter in the Alleles column is the effect allele for specified SNP, e.g., For SNP 
rs2444240; T is effect allele not G 
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Chapter 3 Genome-wide association study and pathway-based 
association study for corneal astigmatism in Australian 
cohorts of northern European ancestry 
This section is published as: 
Yazar S
*
, Mishra A
*
, Ang W, Kearns LS, Mountain JA, Pennell C, Montgomery GW, Young TL, 
Hammond CJ, Macgregor S, Mackey DA, Hewitt AW. Interrogation of the platelet-derived growth 
factor receptor alpha locus and corneal astigmatism in Australians of Northern European ancestry: 
results of a genome-wide association study. Mol Vis. 2013 Jun 6;19:1238-46. Print 2013. *Authors 
contributed equally 
3.1 Summary and its Impact 
A cornea with an irregular shape distorts the focus of light rays on the retina; this condition is 
known as corneal astigmatism
138
 (figure 3.1). In normal eye the spherical shaped cornea allows light 
rays to be refracted equally from different surfaces such that refracted rays focus onto the retina to 
create a sharp image. However in the astigmatic eye the retina is oval shaped with steeper curves 
and flatter regions, causing variation in the refraction of light rays from different surfaces and hence 
the light rays focus either before retina or create multiple focal point onto retina causing blurred 
vision. 
 
Figure 3.1: A normal and an astigmatic eye (Source: 
http://humaneyesr.wikispaces.com/Nearsightedness,+Farsightedness+and+Astigmatism, reproduced 
with permission from ©2014 Tangient LLC) 
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Corneal astigmatism is one of the most common ophthalmic conditions worldwide, with very high 
heritability (around 63%)
139
. The rs7677751 SNP in PDGFRA gene was reported associated with 
corneal astigmatism in individuals of Asian ancestry
83
. This chapter aimed to replicate association 
of rs7677751 with corneal astigmatism in the Australians of northern European ancestry. 
This chapter demonstrates initial GWAS on corneal astigmatism in individuals of northern 
European ancestry, with a total sample size more than 2700 individuals from the Western Australia 
pregnancy cohort study (Raine), the Twins Eye Study in Tasmania (TEST) and the Brisbane 
Adolescent Twin Study (BATS). This chapter also reports the application of VEGAS-Pathway on 
corneal astigmatism GWAS data. We also performed the gene-based analysis using VEGAS 
approach but none of the genes showed significant association after multiple testing corrections. 
Two major outcomes of this chapter were 1) non-replication of association of rs7677751 with 
corneal astigmatism in the Australians (which was previously reported association in Asians) and 2) 
significant association of the segmentation pathway with corneal astigmatism. Since the publication 
of our findings until now (2015), no genetic association study was reported on corneal astigmatism. 
Hence our initial report on association of the segmentation pathway with corneal astigmatism is yet 
to be validated in an independent sample. Moreover I anticipate the report of initial GWAS will 
help in development of international collaboration to perform large-scale studies to understand the 
genetic basis of corneal astigmatism. 
3.2 Contribution of Candidate 
I performed GWAS on the twin cohort (BATS and TEST) data using the Merlin software
136
. I meta-
analysed the GWAS results from twin cohorts (BATS and TEST) and the population cohort (Raine) 
studies using the software METAL
51
. I performed pathway analysis using VEGAS-Pathway. I 
wrote section of methods describing BATS and TEST cohorts, and joint cohort analysis. I also 
wrote parts of the results and discussion sections. 
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3.3 Contribution of Other Authors 
David Mackey, Stuart Macgregor, Alex Hewitt, Grant Montgomery and Nicholas Martin collected 
the samples for BATS and TEST studies, whereas Seyhan Yazar, Alex Hewitt, David Mackey, 
Jenny Mountain, Wei Ang and Craig Pennell collected samples for Raine study. Seyhan Yazar and I 
collectively wrote the manuscript. Alex Hewitt, David Mackey and Stuart Macgregor contributed to 
the study concept and design, and edited the manuscript. All authors read and approved the 
manuscript. 
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Table 3: Strongest associated, genotyped SNPs for corneal astigmatism identified through genome-
wide meta-analysis following adjustment for age and sex. 
Note: This table is an edited version of table 3 in publication. Chromosomal base pair positions of 
some variants in table 3 in publication are rounded. 
SNP 
C
H
R 
bp 
Allel
e 
Raine (n=1013) TEST/BATS (n=1771) Meta-analysis 
Effect SE p-value Effect SE p-value Beta SE p-value 
rs1151008 12 31988627 G -0.138 0.046 3.07x10-3 -0.15 0.038 7.50x10-5 -0.144 0.03 1.37x10-6 
rs1164064 3 110945090 A 0.212 0.043 9.91x10-7 0.065 0.037 7.50x10-2 0.134 0.028 1.86x10-6 
rs11841001 13 75147104 A 0.185 0.072 1.10x10-2 0.195 0.057 6.30x10-4 0.208 0.045 4.31x10-6 
rs7651778 3 157819249 C 0.096 0.043 2.64x10-2 0.139 0.036 9.30x10-5 0.126 0.028 4.76x10-6 
rs11859036 16 78863052 A 0.145 0.043 8.74x10-4 0.107 0.037 3.60x10-3 0.128 0.029 7.03x10-6 
rs438465 6 169562306 C -0.211 0.058 2.70x10-4 -0.143 0.051 5.50x10-3 -0.173 0.039 7.22x10-6 
rs979976 2 137485172 A 0.163 0.047 4.81x10-4 0.102 0.038 7.20x10-3 0.134 0.03 7.52x10-6 
rs4805442 19 34780233 A -0.192 0.06 1.48x10-3 -0.141 0.05 4.40x10-3 -0.168 0.038 1.18x10-5 
rs10079889 5 33011247 A 0.165 0.052 1.50x10-3 0.124 0.043 4.30x10-3 0.145 0.033 1.38x10-5 
rs2116538 2 137485890 A -0.162 0.052 1.92x10-3 -0.135 0.044 2.10x10-3 -0.146 0.034 1.63x10-5 
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Chapter 4 Application of GWAS and post-GWAS approaches to 
identify genes and pathways associated with vertical cup disc 
ratio 
This section is published as: 
Springelkamp H*, Höhn R*, Mishra A*, Hysi PG*, Khor CC*, Loomis SJ*, Bailey JN, Gibson J, 
Thorleifsson G, Janssen SF, Luo X, Ramdas WD, Vithana E, Nongpiur ME, Montgomery GW, Xu 
L, Mountain JE, Gharahkhani P, Lu Y, Amin N, Karssen LC, Sim KS, van Leeuwen EM, Iglesias 
AI, Verhoeven VJ, Hauser MA, Loon SC, Despriet DD, Nag A, Venturini C, Sanfilippo PG, 
Schillert A, Kang JH, Landers J, Jonasson F, Cree AJ, van Koolwijk LM, Rivadeneira F, Souzeau 
E, Jonsson V, Menon G; Blue Mountains Eye Study—GWAS group, Weinreb RN, de Jong PT, 
Oostra BA, Uitterlinden AG, Hofman A, Ennis S, Thorsteinsdottir U, Burdon KP; 
NEIGHBORHOOD Consortium; Wellcome Trust Case Control Consortium 2 (WTCCC2), Spector 
TD, Mirshahi A, Saw SM, Vingerling JR, Teo YY, Haines JL, Wolfs RC, Lemij HG, Tai ES, 
Jansonius NM, Jonas JB, Cheng CY, Aung T, Viswanathan AC, Klaver CC, Craig JE, Macgregor 
S, Mackey DA, Lotery AJ, Stefansson K, Bergen AA, Young TL, Wiggs JL, Pfeiffer N, Wong TY
#
, 
Pasquale LR
#
, Hewitt AW
#
, van Duijn CM
#
, Hammond CJ
#
 Blue Mountains Eye Study-GWAS 
group; NEIGHBORHOOD Consortium; Wellcome Trust Case Control Consortium 2 WTCCC2. 
Meta-analysis of genome-wide association studies identifies novel loci that influence cupping and 
the glaucomatous process. Nat Commun. 2014 Sep 22;5:4883. doi: 10.1038/ncomms5883. *These 
authors contributed equally to this work. 
#
 These authors jointly directed this work. 
Note: Please refer Appendix A for the supplementary information. 
4.1 Summary and its Impact 
This chapter demonstrates the application of an endophenotype approach to identifying complex 
disease risk loci for eye disease. It is also a nice demonstration of an application of gene-based and 
pathway-based association approaches using the software VEGAS and Pathway-VEGAS 
respectively. It reports novel loci not found associated with vertical cup disc ratio (VCDR) through 
single marker approach, identified using a gene-based approach in VEGAS
140
. It also reports the 
significant association of a pre-specified gene ontology pathway with VCDR using the Pathway-
VEGAS approach. 
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Figure 4.1: Geometric model of optic nerve head (ONH) with cross sectional profile 
and projected image. (A) Locating cup margin points in deformable model algorithm. (B) Cross 
sectional profile of 3D ONH model, with definitions of various ONH parameters, i.e., disc area, rim 
area, cup area, rim volume and cup volume. (C) The definitions of vertical cup disc ratio and cup 
disc area ratio. (Source: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2913866/figure/g004/, 
reproduced with permission from ©2010 Optical Society of America.)  
Glaucoma is the second most common cause of blindness
141
. It is characterised by the excavation of 
optic nerve head (ONH) resulting in optic cup enlargement
141
. VCDR is a key parameter for clinical 
assessment and follow up of glaucoma patients
141
. It compares the vertical diameter of cup portion 
with the vertical diameter of the whole disc (refer to figure 4.1). 
This study as a part of the international glaucoma genetics consortium (IGGC) reports the largest 
GWAS meta-analysis for VCDR with 21,094 and 6,784 individuals of European and Asian 
ancestries respectively. It systematically reports the findings obtained at the discovery stage, 
replication stage and finally meta-analysis stage. Meta-analysis stage of single marker GWAS 
reports 18 loci (10 novel loci) associated with VCDR. 6 out of 10 novel loci associated with VCDR 
showed nominal significant (p-value < 0.05) association in glaucoma cohorts. To identify loci with 
joint marker effects, a gene-based association study was performed using VEGAS separately for 
European and Asian ancestry data and the results were further meta-analysed. Gene-based 
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association analysis using VEGAS identified two novel loci not identified by single marker GWAS 
approach. To further identify whether there is an enrichment of gene-based test statistics in pre-
specified gene ontology pathways, a pathway based association test was performed using our in 
house software Pathway-VEGAS. This analysis reported significant association (at Bonferroni 
threshold) of the “negative regulation of cyclin-dependent protein kinase activity” pathway with 
VCDR. 
Recently Tham et al.
142
 created genetic risk score using 18 VCDR associated loci and showed 
individuals of the Asian ancestry in the highest tertile of genetic risk score had 2.09, 2.31 and 4.10 
times increased risk of glaucoma, primary open angle glaucoma and primary angle closure 
glaucoma respectively. 
4.2 Contribution of Candidate 
I contributed to the manuscript by performing gene-based association test and pathway based 
association test. I wrote part of the manuscript including Methods section under heading Gene-
based Test using VEGAS, Pathway-analysis using Pathway-VEGAS, Results section under heading 
Gene-based test and Pathway analysis, and Discussion section discussing gene-based and pathway-
based results under supervision of Stuart Macgregor. I read the final manuscript and given 
significant input at the final editing stage. 
4.3 Contribution of Other Authors 
N.P., T-Y.W., L.R.P., A.W.H., C.M.v.D. and C.J.H. jointly directed this work. H.S., R.H., P.H., T-
Y-.W, L.R.P, A.W.H., C.M.v.D and C.J.H. performed analyses and drafted the manuscript. J.B.J, 
A.C.V., C.C.W.K, J.E.C, S.M, D.A.M., A.J.L, J.L.W., N.P., T-Y.W., L.R.P., A.W.H., C.M.v.D. and 
C.J.H. jointly conceived the project and supervised the work. W.D.R., E.V., M.E.N., G.W.M., L.X., 
J.E.M, Y.L., N.A., L.C.K., K-S.S., E.M.v.L., A.I.I., V.J.M.V., M.A.H., S-C.L., D.D.G.D., A.N., 
C.V., P.G.S., A.S., J.H.K., J.L., F.J., A.J.C., L.M.E.v.K., F.R., E.S., V.J., G.M., R.N.W., 
P.T.V.M.d.J., B.A.O., A.G.U., A.H., S.E., T.D.S., A.Mirshahi, S-M.S., J.R.V., Y-Y-T., R.C.W.W., 
H.G.L., E-S.T., N.M.J., C-Y.C. and T.A. were responsible for study-specific data. H.S., S.J.L, 
J.N.C.B., J.G., G.T., P.G., U.T., K.P.B., J.L.H., J.E.C., A.J.L, K.S. and J.L.W. were involved in the 
genetic risk score analysis. S.F.J., X.L., A.A.B.B. and T.L.Y. performed the data expression 
experiments. C-C.K., W.D.R., P.T.V.M.d.J., H.G.L., N.M.J., J.B.J., A.C.V., C.C.W.K., J.E.C., 
S.M., D.A.M., A.J.L. and J.L.W. critically reviewed the manuscript.  
48 | P a g e  
 
 
49 | P a g e  
 
 
50 | P a g e  
 
 
51 | P a g e  
 
 
52 | P a g e  
 
 
53 | P a g e  
 
 
54 | P a g e  
 
 
  
55 | P a g e  
 
Chapter 5 VEGAS2: An extension of VEGAS that use 1000 
Genomes reference sets and provide test for X chromosome 
This section is published  as: 
Mishra A, Macgregor S. VEGAS2: Software for More Flexible Gene-Based Testing. Twin Res. 
Hum. Genet. 2014 Dec 18:1-6. 
5.1 Summary and its Impact 
This chapter reports on the VEGAS2 software, which is an important addition to existing gene-
based association approaches. VEGAS2 is an extension of VEGAS approach
140
, which is one of the 
most popular gene-based association approaches available. Two major limitations of VEGAS are 
that the HapMap2 reference set is used to model the correlation between SNPs and only autosomal 
genes are considered. 
HapMap2 has now been superseded by the 1000 Genomes reference set
25
. The 1000 Genomes 
phase 1 data can improve the LD estimates given the increase in panel size (e.g. for European 
ancestry there are 379 individuals compared to 90 in HapMAP phase 2). VEGAS2 was developed 
to use the 1000 Genomes data for gene-based tests. 
Although early GWASs frequently ignored the X chromosome, it is now commonly included. X 
chromosomes have some special characteristics compared to autosomes, for example males have a 
single copy; females have two copies and one copy in females is fully or partly inactivated. These 
special characteristics of the X chromosome require a separate statistical testing model for 
association analysis compared with autosomes. There are two popular models employed to perform 
GWAS analysis of the X chromosome data. In this chapter, we have demonstrated the performance 
of VEGAS2 in both these model settings using melanoma case-control data. 
Recently Goes et al.
143
 applied VEGAS2 on a GWAS of schizophrenia in an Ashkenazi jewish 
sample of 592 cases and 505 controls. Although none of the genes reached the genome-wide 
significance but interestingly genes in the chromosome 22q11.2 deletion region (TRMT2A, ARVCF, 
and DGCR8) were among the top findings. These genes might be responsible for shared aetiology 
between del22q11 syndrome and schizophrenia
144
. 
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5.2 Contribution of Candidate 
I contributed in planning, development and writing of the manuscript under supervision of Stuart 
Macgregor. 
5.3 Contribution of Other Authors 
Stuart Macgregor supervised the project and edited the manuscript. 
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Chapter 6 VEGAS2Pathway: A pathway analysis approach for 
GWAS summary data 
 
This chapter is written in a manuscript format. It will be further revised and submitted for 
publication around October 2015. 
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6.1 Introduction 
Genome Wide Association Study (GWAS) have substantially improved our understanding of the 
genetic basis of various complex human phenotypes
59
. GWAS typically tests the association of each 
single nucleotide polymorphism (SNP) with trait of interest. To control false positives, frequently 
only genome wide significant SNPs (p-value < 5 × 10
-8
) are reported, with relatively little attention 
paid towards the remaining SNPs. Finding genome-wide significant small risk effect variants 
associated with a polygenic complex trait requires a large sample size
145
. Even in situations where 
GWAS have been carried out with sample sizes in hundreds of thousands individuals
146
, the 
variants identified only account for a small proportion of heritable component of disease risk
147
. 
Although unambiguously identifying which of the sub-threshold genome-wide significant SNPs are 
associated with a trait is not possible with current sample sizes, for many complex traits it has been 
possible to show that there is a substantial polygenic contribution which explains much more of the 
heritability
32; 148-150
. 
It is well established that the genes work in concert, with many attempts to characterise how genes 
work together in pathways
91; 151; 152
. Pathway-based association strategies that use established gene 
sets are becoming increasingly popular as a complementary method to GWAS. These strategies 
map the SNPs’ effects to the genes and then test the association of the combined effects of 
biologically or functionally related genes with the phenotype under consideration. Since relatively 
few SNPs in a study will reach genome-wide significance in a given study, it may not be clear that a 
subset of them act within a particular pathway. By considering additional sub-threshold SNPs then 
it may be possible to 1) prioritize SNPs for follow up based on the pathway they lie in and 2) to 
better define the pathways involved in the trait, leading to insight into the underlying molecular 
mechanisms. 
Although pathway-based association strategies have several advantages, further methodological 
development is required. Methods reported for pathway-based association tests include GenGen
92
, 
ALIGATOR
93
 (Association LIst Go AnnotaTOR), MAGENTA
117
 (Meta-Analysis Gene-set 
ENrichment of varianT Associations), INRICH
118
 (Interval enRICHment analysis) (Refer chapter 1 
for detailed discussion on these strategies). Methods based on the hyper geometric distribution are 
quick to compute but may show high type 1 error
118
. Alternatively permutation based approaches 
are possible but are computationally demanding and require genotype data. Some of these 
approaches are based on assumptions, which may not hold true in the context of the real genetic 
architecture. As highlighted by Holmans et al.,
93
 the ALIGATOR approach is based on assumption 
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that the linkage disequilibrium (LD) between SNPs within a gene is constant, but LD between SNPs 
could be variable (regions with high LD SNPs and low LD SNPs). MAGENTA
117
 on the other hand 
uses the test statistics of only one gene (calculated using a top SNP) to represent a whole region of 
neighboring genes belonging to same pathway. This may not be a realistic assumption because 
some regions have been shown to harbor many independent markers with profound effect on the 
variation in a phenotype
85
. 
In the past few years, several reviews have been published discussing the issues related to the 
pathway-based association tests
145; 153; 154
. Some of the potential confounding sources highlighted 
includes: 1) inadequate modeling of the LD pattern within a gene; 2) overlapping or neighboring 
genes belonging to the same pathway, which may lead to counting a particular signal multiple 
times; 3) gene set size and number of SNPs in a gene. Here we report VEGAS2Pathway, a versatile 
pathway-based approach for GWAS data that accounts for these confounders. We report its 
implementation in user-friendly web-based and command line Unix versions. 
We apply our method on the endometriosis GWAS summary data published by Painter et al.
129
. 
Endometriosis is a common gynecological disease affecting women of reproductive age
155
. It is 
characterised by the growth of endometrial cells outside of the uterus. It is a heterogeneous disease 
in the context of its natural history, disease burden, extent of inflammation, state of progression, and 
phenotypic presentation of lesions and symptoms
156
. Endometriosis is a common genetic disease 
with a heritability around 51%
157
. 
6.2 Methods 
6.2.1 VEGAS2Pathway data repository 
6.2.1.1 Gene Data 
The ‘gene2accession’ file annotated through the Reference GRCh38 Primary Assembly was 
downloaded on 19
th
 July 2014 from NCBI ftp server. The mRNA coding refseq genes (refseq id 
starts with NM_) with complete genomic molecule (refseq id starts with NC_) with either 
VALIDATED or REVIEWED statuses were extracted. Four genes (CAPN8, ECSCR, GALNT9, and 
GRK1) showed two non-overlapping start and end genomic accession positions. These two variable 
positions for respective four genes were less than 55kb away from each other suggesting they are 
isoforms rather than distinct genes, so we merged them to form a gene with start being smallest of 
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start positions and end being the largest of the end positions. The final file contained 17571 genes 
across the autosomes and the X chromosome. 
6.2.1.2 1000 Genomes data 
The 1000 Genomes phase 1 release version 3 data annotated on Reference GRCh37.p13 Primary 
Assembly was downloaded on 22
nd
 May 2014 from NCBI website (ftp://ftp-
trace.ncbi.nih.gov/1000genomes/ftp/release/20110521/). Using vcftools package
158
, genotypes from 
European ancestry samples were filtered to extract SNPs with minor allele frequency above 1% and 
a Hardy-Weinberg Equilibrium test p-value above 1 × 10
-6
. The annotations of these alleles were 
updated to Reference GRCh38 Primary Assembly using the LiftOver package 
(http://genome.sph.umich.edu/wiki/LiftOver). 2664 SNPs present in the GRCh37 are not annotated 
in Reference GRCh38 Primary Assembly. 1855 SNPs in unplaced contigs were removed. Similar 
processing was applied to the Asian, African and American ancestry samples. 
6.2.1.3 Molecular Signature Database (MSigDB) pathway data 
The curated and gene ontology (GO) gene sets of Molecular Signature Database (v4.0 MSigDB)
126
 
were downloaded on the 24
th
 July 2014 from 
http://www.broadinstitute.org/gsea/msigdb/collections.jsp. The annotations file was processed to 
make a two-column tab delimited file containing each gene’s symbol and its annotated pathway id. 
This file contains 6176 unique pathways with pathway size range in 5 to 2137. We filtered 
pathways with more than 1000 genes since they have less specificity. For example, the 
CYTOPLASM pathway that has genes annotated by the GO term GO:0005737 does not provide 
any specific information. This processing resulted in 6128 pathways. 
6.2.1.4 Strategy to prepare VEGAS2Pathway database 
The MSigDB annotation data, GRCh38 annotated gene list and GRCh38 annotated 1000 Genomes 
data files were used to make the VEGAS2Pathway repository files. The MSigDB annotation and 
gene list files were merged. Frequently within a pre-specified pathway, two or more included genes 
lie close together on a chromosome. We addressed this issue by preparing neighboring gene clusters 
where two or more annotated gene sites were less than 500kb away and in the a common pathway, 
they were merged to form a gene cluster comprising all the SNPs in the relevant genes. The gene 
clusters were analysed as if they were single, large, genes with the previously described simulation 
method in VEGAS
140
 used to correct SNPs that were in LD. Following this process, all the genes or 
gene clusters belonging to a particular pathway are more than 500kb away from each other. To 
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consider the variants in the regulatory region, SNPs within 50kb boundary of the coding region of a 
gene are included. VEGAS approach is based on the simulation of LD matrix of SNPs within a gene 
boundary (optionally, with a flanking region added)
140
. As an increase in the number of SNPs in a 
gene or gene cluster exponentially raises the computation burden, we implemented the ‘-SNPlimit’ 
parameter that limits the number of SNPs in a gene boundary. By default VEGAS2Pathway uses 
2000 SNP limit in a gene or a gene cluster, if the number of SNPs in a gene are more than 2000 
then 2000 SNPs are randomly chosen for the gene-based test. 
6.2.2 VEGAS2Pathway strategy 
After calculating the gene-based test statistics for all genes and gene clusters using the VEGAS 
approach, genes were assigned to respective pathways. For each pathway gene-based tests statistics 
were converted to upper tail χ2 statistics with 1 degree of freedom and summed. Under a polygenic 
model and assuming a non-competitive test, larger pathways will typically be more significant than 
smaller pathways. Since we believe the genetic architecture for many complex traits will be 
polygenic, a non-competitive test is unlikely to provide useful results (as large pathways will be 
much more likely to be significant than small ones). Instead, we implemented a competitive test in 
which each pathway is benchmarked against the ‘typical’ pathway of the same size. Specifically we 
corrected for pathway size bias by adopting a re-sampling approach where the same number of 
genes as present in a pathway are repeatedly drawn at random from all set of genes used in the 
study and summed. The empirical p-value of association for a pathway is calculated by comparing 
the observed summed χ2 statistics with set of re-sampled summed χ2 statistics. Figure 1 describes 
the schematic representation of the VEGAS2Pathway strategy. 
6.2.3 Simulation to establish properties of VEGAS2Pathway 
The MSigDB pathway annotation database comprises the pathways from different sources 
including genes reported in research articles and gene-sets reported in specialised resources GO, 
KEGG, TRANSFAC and L2L
120
. In this database, there is frequently overlap in the set on genes 
included in different pathways. Since these pathways are not independent, application of traditional 
multiple testing methods such as Bonferroni correction, Šidák correction and false discovery rate 
(FDR) procedure would be inappropriate. We applied VEGAS2Pathway on 1000 simulated 
quantitative phenotypes with standard normal distribution N(0, 1). We extracted the top-pathway 
test statistics from 1000 simulations to allow estimation of a significance threshold (assessment of 
how differently the results for the 6128 pathways behave relative to the situation where for example 
there were 6128 completely independent pathways).  We also used the set of 1000 simulations to 
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assess the correlation between gene size and gene p-value, and between pathway-size and pathway 
p-value. 
 
Figure 6.1: Schematic representation of VEGAS2Pathway strategy: After reading in the 
two column (SNP id and GWAS p-value) text file, SNPs are assigned to pathways via genes. If the 
genes belonging to a pathway are less than 500kb away then a gene-based test statistic is calculated 
by making a cluster of all neighbouring genes, if not then a gene-based test statistic of an individual 
gene was calculated. In this way, VEGAS2Pathway make sure that all gene and gene cluster based 
test statistics assigned to a pathway are at least 500 kb away from each other. The gene and gene 
cluster based test statistics are then summed to compute a statistic for each pathway. Empirical p-
values for each pathway are computed by comparing resampling replicate sets of gene-based test 
statistics with the results from the actual data.  
Summary Data 
Assign SNPs to genes and genes to 
pathways
Calculate empirical p-value of 
association through resampling of the 
gene–based tests statistics 
 
 
Are genes in a common pathway < 500kb away? 
 
Yes: Make a cluster of 
neighbouring genes and 
perform the gene-based test 
using VEGAS approach 
No: Perform the 
gene-based test 
using the VEGAS 
approach
Summarize the gene-based test 
statistics into pathways
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6.2.4 Application on GWAS summary data 
As a proof of concept we applied VEGAS2Pathway on the endometriosis GWAS summary data 
obtained from Painter et al
129
. They performed GWAS on 3154 endometriosis cases and 6981 
controls of northern European ancestry. We used 1000 Genomes phase 1 European data as a 
reference for VEGAS2Pathway analysis with default options. 
6.3 Results 
6.3.1 Establishing type 1 error cut off 
Applying Bonferroni correction for multiple testing of overlapping pathways would be a 
conservative approach. To estimate the 5% significance threshold for these overlapping pathways, 
we applied VEGAS2Pathway approach on GWAS summary files from 1000 simulated quantitative 
phenotypes with standard normally distributed trait values. Figure 2 shows the scatter plot of top 
pathway log10 p-values on simulated data. The 5% significance threshold for VEGAS2Pathway- 
 
Figure 6.2:  The scatter plot of absolute log10 p-values of top pathway of 1000 
simulated replicates. The line separates the 5% of top p-values  
70 | P a g e  
 
-analysis, taking into account the multiple testing of 6128 correlated pathways on the MSigDB 
pathway set is 1.09 × 10
-5
 (since 0.05/4597 = 1.09 × 10
-5
, we are correcting for 4597 effectively 
independent tests). In comparison, if we were to Bonferroni correct for all 6128 MSigDB pathways, 
our threshold for significance would be 0.05/6128 = 8.16 × 10
-6
. 
Both gene-size and pathway-size affect the pathway analysis. If there is a positive correlation 
between a gene’s size and its gene-based p-value then pathways with an excess of bigger genes in 
them will repeatedly appear as significant in pathway analysis. Similarly a pathway containing large 
number of genes may appear significant merely by chance only. VEGAS2Pathway uses the VEGAS 
approach to perform gene-based analysis. In addition to accounting for LD between SNPs we 
expect that the VEGAS approach will also deal appropriately with gene size. To account for 
pathway size, VEGAS2Pathway compares each gene set with multiple resamples of the sets with 
the same number of genes. This approach should deal appropriately with different pathway sizes. 
To assess performance of VEGAS2Pathway in practice, we calculated the Pearson’s correlation 
coefficient between gene size and gene-based p-value, and pathway size and empirical p-value of 
pathway association. Table 2 shows the summary of correlation distribution in 1000 replicates. The 
correlation is typically close to 0 (between gene size and gene-based p-value: median -2 × 10
-3
, with 
90% of simulation replicates in a -0.03 to +0.03 range, and between pathway size and pathway-
based p-value: median 3 × 10
-3
, with 90% of simulation replicates in a -0.05 to +0.06 range). 
Furthermore, in supplementary figure 1 we show that the type 1 error rate is independent of the 
pathway size. The mean type 1 error rate for all pathways is 0.049. 
Table 6.1: Distribution of the correlation between gene size and gene-based p-value, 
and correlation between pathway size and pathway-based p-value from 1000 
simulated GWAS data 
 Correlation between gene 
size and gene-based p-value 
Correlation between 
pathway size and pathway-
based p-value 
Min -0.05 -0.10 
5% -0.03 -0.05 
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25% -0.01 -0.02 
50% (median) -2 × 10
-3
 3 × 10
-3
 
75% 0.01 0.03 
95% 0.03 0.06 
Max 0.04 0.11 
Mean -1 × 10
-3
 4 × 10
-3
 
6.3.2 Application of VEGAS2Pathway on Endometriosis GWAS summary data 
We performed pathway analysis on endometriosis (all stages) GWAS summary data reported by 
Painter et al
129
. The pathway test statistics genomic inflation is 0.93. No pathway reached genome-
wide significant threshold 1.09 × 10
-5
. Table 2 show the top five pathways observed in pathway 
analysis. 
Table 6.2: Top five pathways from pathway analysis of endometriosis GWAS 
summary data 
MSigDB Pathway ID Length p-value Genes and gene clusters 
DAWSON_METHYLATED_IN_LY
MPHOMA_TCL1 54 4.9 × 10-4 
PCDH10_RNF180_PRR16_FOXC1_ID
4_NRSN1_TBX18_EPHA7_FAM184A
_CLVS2_KIAA0408_SAMD5_ESR1_H
OXA2_TNS3_AUTS2_AJAP1_FOXD3_
CADPS2_TMEM229A_SOX17_LPHN2
_BHLHE22_RUNX1T1_FAM49B_PTP
RD_CDKN2A_GAS1_EGR2_ZDHHC5_
NCAM1_SPRY2_SOX1_FOXG1_MDG
A2_TMEM30B_GOLGA5_TNFAIP2_C
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LEC16A_IRX3_TSHZ3_PLCB4_ISM1_
MACROD2_SLC24A3_HMGN1_KLHL2
9_PKP4_FIGN_STK39_EVX2/HOXD13
_OSBPL6_OPRD1_ARHGEF26 
REACTOME_DEFENSINS 12 6.9 × 10-4 
TLR2_DEFB110_CCR6_PRSS2_DEFB1
/DEFA6/DEFA4/DEFA1/DEFA3/DEFA
5/DEFB4B/DEFB103B/DEFB104B/DE
FB106B/DEFB105B/DEFB107B/DEFB
107A/DEFB105A/DEFB106A/DEFB10
4A/DEFB103A/DEFB4A_ART1_CD4_
DEFB125/DEFB126/DEFB127/DEFB1
29/DEFB132_DEFB118/DEFB119/DE
FB121/DEFB123_CCR2_DEFB131_TL
R1 
REACTOME_BETA_DEFENSINS 9 1.7 × 10-3 
TLR2_DEFB110_CCR6_DEFB1_DEFB1
25/DEFB126/DEFB127/DEFB129/DEF
B132_DEFB118/DEFB119/DEFB121/
DEFB123_CCR2_DEFB131_TLR1 
BIOCARTA_GH_PATHWAY 27 1.9 × 10-3 
GHR_PIK3R1_SRF_PIK3CG_JAK2_HR
AS_INS_PTPN6_HNF1A_MAP2K1_SH
C1_SOCS1_PRKCB_MAPK3_SLC2A4_
STAT5B/STAT5A_GH1_PRKCA_GRB2
_INSR_PLCG1_MAPK1_SOS1_IRS1_R
AF1_RPS6KA1_PIK3CA 
PETRETTO_BLOOD_PRESSURE_
UP 11 1.9 × 10-3 
MUSK_NXPH4_RHOV_MAP1A_MYO
1E_NTRK1_ZBTB7A_KHSRP_MOCS3_
CHIT1_KPNA6 
The top pathway DAWSON_METHYLATED_IN_LYMPHOMA_TCL1 pathway (p-value = 4.9 × 
10
-4
) consists of the genes hyper-methylated in lymphoma tumours of transgenic mice over 
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expressing the TCL1 gene
159
. The second and third pathways REACTOME_DEFENSINS and 
REACTOME_BETA_DEFENSINS represent the set of genes in the defensin family and its sub 
family beta-defensins. Defensins are cysteine rich antimicrobial peptides
160
. The fourth pathway 
BIOCARTA_GH_PATHWAY contains the genes involved in growth hormone signalling pathway. 
The fifth pathway PETRETTO_BLOOD_PRESSURE_UP is a set of genes positively correlated 
with systolic blood pressure. Table 3 shows the lists of genes that are driving the association test 
statistics of the top pathway DAWSON_METHYLATED_IN_LYMPHOMA_TCL1. Refer 
supplementary table 1-4 for the list of genes driving test statistics of following top four pathways. 
Table 6.3 List of genes in DAWSON_METHYLATED_IN_LYMPHOMA_TCL1 pathway 
with gene-based p-value < 0.05 
Gene Chromosome Start Stop p-value 
CLEC16A 16 10944487 11182188 1.4 × 10
-3
 
ID4 6 19837347 19842199 6.3 × 10
-3
 
SLC24A3 20 19212645 19722896 6.4 × 10
-3
 
FAM184A 6 118959828 119149192 6.4 × 10
-3
 
SAMD5 6 147508691 147570020 6.5 × 10
-3
 
ESR1 6 151690495 152103273 7.4 × 10
-3
 
RNF180 5 64165305 64372876 7.6 × 10
-3
 
TSHZ3 19 31274944 31349283 9.4 × 10
-3
 
FAM49B 8 129839592 130016650 0.01 
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FIGN 2 163604936 163736107 0.03 
CADPS2 7 122318423 122886758 0.05 
AUTS2 7 69598918 70792898 0.05 
6.3.3 Web-based and unix command line implementations of VEGAS2Pathway 
VEGAS2Pathway was developed in the R and perl programming languages to work in a unix 
command line environment. The installation and usage manual, VEGAS2Pathway data repository, 
scripts and the online version can be access through https://vegas2pathway.qimrberghofer.edu.au/. 
Both the web-based and command line versions are easy to use and require only a two-column 
GWAS summary file with ‘rsID’ ‘p-value’ 
VEGAS2Pathway perform gene/gene clusters based test using VEGAS approach before performing 
a pathway analysis. This is a time consuming step. In the web-based implementation, this step is 
parallelised by chromosome, significantly improving its performance. In the VEGAS2 paper 
(chapter 5), we reported that all imputed SNPs inclusion does not give any inherent advantage over 
the r
2
 > 0.99 pruned list of SNPs. Hence in the web-based version by default VEGAS2Pathway 
applies the “r2 >0.99” pruning using the 1000 Genomes reference dataset for specified population 
(if desired, users can select the option of ‘no pruning’). 
6.4 Discussion 
We present the novel but simple approach for pathway analysis of GWAS data using MSigDB 
pathway definitions. Most of the pathway analysis approaches reported previously has some 
inherent issues based on the assumptions made. Gene-based calculation in ALIGATOR is based on 
the assumption that LD within genes is constant. Holmans et al.
93
 highlighted the difficulty in 
accounting for variable LD without resorting to computationally intensive permutation-based 
methods. Additionally ALIGATOR approach requires users to pre-specify a threshold for including 
SNPs in the pathway test, with less significant SNPs ignored. A computationally efficient 
simulation approach (VEGAS) is used here to calculate gene-based test statistics that account for 
variable LD patterns within a gene and gives similar results as a permutation approach. 
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Other approaches such as GenGen and MAGENTA consider only a top SNP within a gene 
boundary to calculate a gene-based test statistics. Yang et al.
85
 reported number of independent 
variants belonging to the same gene that have significant effect on the height. Hence, MAGENTA 
and GenGen may lose significant information. The VEGAS2Pathway approach uses all the SNPs 
within a gene boundary and this may increase the power of pathway analysis.  
Similarly, some approaches (e.g. MAGENTA) drop neighboring genes while keeping one for 
pathway analysis to account for LD between SNPs in closely located genes. These approaches lose 
power since the variant in the dropped genes could be of biological importance and may have role 
in representing the association test statistics of the concerned region. In VEGAS2Pathway, we make 
a cluster of neighboring genes (within 500kb, since LD rarely extends beyond this) and account for 
LD between nearby SNP using the approach used in VEGAS (i.e. simulation). In addition to the 
adjustment of major confounders in pathway analysis, the implementations of VEGAS2Pathway are 
easy to use. These implementations do not require much pre-processing of input files (as the case in 
INRICH). A user-friendly web-based implementation is provided. 
The current version of VEGAS2Pathway is developed for analysis of MSigDB pathways but it 
could easily be extended to other databases. We have provided the multiple testing cut-off since the 
traditional multiple testing corrections are over-conservative for non-independent pathway tests. 
Wang et al.
153
 highlighted the need to use both the manually curated and the computationally 
predicted pathways. MSigDB have certain advantages over several publically available pathway 
databases
120
: 1) it is designed as the database for the gene set enrichment analysis software;. 2) It 
covers more diverse and wider range of gene set sources and types, including gene-sets for 
publications, gene-sets from pathway databases GO, KEGG, TRANSFAC and L2L; 3) The 
MSigDB pathways are manually curated or acquired through computational means. Apart from 
these advantages the follow up of a pathway is user friendly. For gene sets from publications, the 
MSigDB webpage provides the PubMed ID and pointers to gene sets published by the same author 
and compendia expression profiles of the genes belonging to the gene set. 
We applied VEGAS2Pathway on endometriosis GWAS summary data published by Painter et al
129
. 
In pathway analysis, none of the pathways reached the genome-wide significant threshold 1.09 × 
10
-5
. The most likely reason is the insufficient sample size. The summary data used does not report 
any genome-wide significantly associated SNP with endometriosis and only 70 SNPs show 
association p-value less than 1.0 × 10
-4
. Increased sample size will increase the power of down-
stream pathway analysis. Another reason for non-identification of significantly associated pathway 
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is the genomic coverage of gene-set. Pathways in MSigDB may not include all the genes associated 
with particular biological processes and hence effect of those genes will be ignored in a pathway 
analysis
114
. MSigDB contains pathways from different databases (KEGG, Biocarta, GO etc.) 
pathway definitions for different biological processes from these databases do not agree
161
. This 
leads to many independent tests for same biological process (high multiple testing burden) but each 
pathway under test has less genomic coverage. 
Although none of the pathway found significantly associated (p-value < 1.09 × 10
-5
) with 
endometriosis, the top pathway DAWSON_METHYLATED_IN_LYMPHOMA_TCL1 (p-value = 
4.9 × 10
-4
) suggest the genes that may be involved in regulating common processes such as the 
ability to evade apoptosis, angiogenesis and stem cell like ability of regeneration shared between 
endometriosis and cancer
162
. Endometriosis is defined as an estrogen dependent, benign 
inflammatory disease
163
. Interestingly, one of the genes driving the test statistics of top-pathway is 
ESR1 (Estrogen receptor 1) (gene-based p-value 7.4 × 10
-3
). ESR1 encodes ERα, an important 
predictor of breast cancer. rs2295190 (a SNP 19 kb downstream of ESR1) is associated with 
invasive ovarian cancer risk
164
.  Bulun et al.
165
 proposed ERβ-to-ERα (protein products of ESR2 
and ESR1) expression ratio is critical in the pathology of endometriosis. This is the first GWAS-
based analysis that suggests possible association of ESR1 with endometriosis. ESR1 would be a 
good candidate for further characterisation of shared processes between endometriosis and cancer. 
In summary, we report VEGAS2Pathway approach for pathway analysis of GWAS summary data. 
It corrects different confounders including gene size, pathway size, LD between SNPs within a 
gene, and between neighboring genes. The current version of VEGAS2Pathway uses MSigDB 
database. This approach is implemented in a user-friendly web page and unix command line perl 
script. As a proof of concept, we applied our method on endometriosis data. The top pathway 
contains genes possibly involved in regulating common processes between endometriosis and 
cancer. 
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6.6 Supplementary Figures 
 
Supplementary Figure 6.1: Distribution of type 1 error rate and pathway size 
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6.7 Supplementary Tables 
Supplementary Table 6.1: List of genes in REACTOME_DEFENSINS pathway with 
gene-based p-value less than 0.05. 
Gene Chromosome Start Stop p-value 
TLR1 4 38796254 38805192 5.0 × 10
-4
 
DEFB1/DEFA6/DEFA4/DEFA1/
DEFA3/DEFA5/DEFB4B/DEFB1
03B/DEFB104B/DEFB106B/DEF
B105B/DEFB107B/DEFB107A/D
EFB105A/DEFB106A/DEFB104
A/DEFB103A/DEFB4A 8 6870574 7896714 1.3 × 10
-3
 
PRSS2 7 142770975 142774559 4.4 × 10
-3
 
DEFB125/DEFB126/DEFB127/D
EFB129/DEFB132 20 87709 261095 9.8 × 10
-3
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Supplementary Table 6.2: List of genes in REACTOME_BETA_DEFENSINS pathway 
with gene-based p-value less than 0.05. 
Gene Chromosome Start Stop p-value 
TLR1 4 38796254 38805192 5.0 × 10
-4
 
DEFB1 8 6870574 6878006 1.4 × 10
-3
 
DEFB125/DEFB126/DEFB127/DEFB129/
DEFB132 20 87709 261095 9.8 × 10
-3
 
Supplementary Table 6.3: List of genes in BIOCARTA_GH_PATHWAY pathway with 
gene-based p-value less than 0.05. 
Gene Chromosome Start Stop p-value 
PIK3CG 7 106865277 106908977 4.9 × 10
-4
 
SOCS1 16 11254416 11256181 5.4 × 10
-3
 
INSR 19 7112254 7294327 6.8 × 10
-3
 
GH1 17 63917199 63918837 7.3 × 10
-3
 
HNF1A 12 120978057 121002511 3.6 × 10
-3
 
PRKCB 16 23835978 24220610 0.05 
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Supplementary Table 6.4: List of genes in PETRETTO_BLOOD_PRESSURE_UP 
pathway with gene-based p-value less than 0.05. 
Gene Chromosome Start Stop p-value 
CHIT1 1 203216078 203229731 9.3 × 10
-3
 
MOCS3 20 50958813 50961862 0.01 
KPNA6 1 32108042 32176567 0.03 
KHSRP 19 6413103 6424810 0.05 
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Chapter 7 Discussion and conclusion 
7.1 Overview 
Genome-wide association studies (GWASs) have improved our understanding of the genetic basis 
of many complex traits, but its application on several ophthalmology phenotypes is at initial stage. 
The aims of this thesis were to understand the genetic basis of different ophthalmology traits 
through the application of GWAS and post-GWAS approaches (using both old and new methods). 
This thesis reports GWAS on corneal curvature (a clinically important parameter for the myopia 
and keratoconus) (chapter 2), corneal astigmatism (chapter 3) and vertical cup-disc ratio (VCDR) (a 
clinical parameter for follow-up of glaucoma patients) (chapter 4) in Australian cohorts. In this 
thesis I also report replication of the variants associated with corneal curvature (chapter 2) and 
corneal astigmatism (chapter 3) respectively. I applied post-GWAS methods VEGAS and VEGAS-
Pathway (a new method) on GWAS summary data for corneal astigmatism and VCDR to identify 
additional loci and biological pathway associated with respective phenotypes. Building on the 
VEGAS approach I report the VEGAS2 software (chapter 5), which uses the 1000 Genomes 
resource and provides a test for genes on the X chromosome. Finally, this thesis reports the 
VEGAS2Pathway approach that satisfies most of the criteria outlined for an ideal pathway analysis 
method for GWAS data. 
7.2 Synthesis of Results and Findings 
7.2.1 Independent Replication of GWAS associations 
Chapter 1 details the success of GWAS in finding genes associated with number of phenotypes. To 
validate the reported associations an independent replication is important. 
In chapter 2, I replicated an association, originally reported in Asians
82
, of rs2114039 near 
PDGFRA with corneal curvature in the Australian cohorts. The allele frequency of this SNP is 
similar in samples of both Asian and European ancestries (HapMap 3 reference panels). This cross-
ancestry replication not only validates the PDGFRA association with corneal curvature but also 
generalises its possible role across Europeans and Asians. As shown in chapter 2 (figure 2), 
rs2114039 confers a comparatively lower effect in our sample than in the Asians studies. Göring et 
al.
166
 reported that in a genome-wide scan estimates of a locus specific effect gets maximise, it is 
likely the effect estimated in a GWAS in Asian samples were maximised. Recently the same 
Singaporean group reported a meta-analysis in collaboration with Japanese and Chinese groups
167
. 
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They identified a new top SNP rs1800813, in LD (r
2
 = 0.68, in Asians) with rs2114039, associated 
with corneal curvature. The effect estimates for rs1800813 in their replication sample (Chinese and 
Japanese) show similar estimate reported in our study for rs2114039 in PDGFRA. This finding is 
consistent with the original estimated effect size at rs2114039 from the initial GWAS being 
upwardly biased. 
Another variant rs6540964 in FRAP1, associated with corneal curvature in Asians, is not replicated 
in the Australian samples. The allele frequency of this SNP is variable across different ancestries 
(HapMap reference panel). The LD pattern between rs6540964 and nearby SNPs is different in 
Asians compared to Europeans (refer to figure 7.1), and this difference might be the cause of the 
non-replication. The allele frequency and LD structure (refer to figure 7.1) differences in Asians 
and Europeans ancestry samples, suggests rs6540964 may not be the causal variant and the weaker 
LD between rs6540964 and the unknown causal variant did not capture the possible association 
signal of the locus in our sample. Assuming the underlying risk variant is the same across different 
ancestries, by leveraging the LD and allele frequency differences of genetic markers across 
ancestries the region of risk association can be narrow down. Recently Wu et al.
168
 localised the 
functional variant P446L for association signal at GCKR lipid loci. They found that there are seven 
and six variants in high LD with P446L in Europeans and Asians (1000 Genomes reference panel) 
but no variant in high LD with P446L in African American samples. 
Following on from the study of corneal curvature, attempts have been made to identify genes 
underlying corneal astigmatism. Corneal astigmatism is an ophthalmic condition in which parallel 
rays entering through an aberrant cornea fail to focus on a single point
169
. A GWAS meta-analysis 
of more than 8000 Asian individuals reported association of variants in PDGFRA with corneal 
astigmatism
83
. In Chapter 3, using Australian samples I could not replicate the top SNP rs7677751 
associated with corneal astigmatism in the Asians. The frequency of T allele in Raine (0.13) and 
BATS/TEST (0.12) samples is comparatively lower than that in Asians (~0.23). The smaller allele 
frequency reduces the power of association test
170
. The effect estimates (odds ratio) of A allele for 
corneal astigmatism across Asian studies range between 1.04 to 1.35. Our samples of ~2700 consist 
of individuals from same families. Assuming 2000 unrelated individuals (say 1000 cases 1000 
controls) our sample gives 71% and 96% replication power (p-value < 0.05) for allele frequencies 
0.12 and 0.23 respectively, for an allele with genotypic relative risk 1.14 (in an additive model) 
(These calculation were carried out using genetic power calculator
137
, case-control for discrete 
trait). In addition to the allele frequency and LD differences in Asians and our samples of European 
ancestries, the loss of power (due to comparatively smaller allele frequency in our sample than 
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Asians) might be one of the reasons for non-replication of rs7677751. The power can be improved 
by increasing sample size. 
 
 
Figure 7.1: rs6540964 regional LD plots for HapMap release 22 CEU samples versus 
HapMap release 22 CHB+JPT samples (plotted using SNAP package171) 
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7.2.2 Genome-wide Association studies on corneal curvature, corneal 
astigmatism, and vertical cup-disc ratio 
Chapter 2 and chapter 3 reports initial GWAS on corneal curvature and corneal astigmatism in 
Australians of northern European ancestry samples. In both studies, no SNP reached the genome-
wide significant threshold of p-value < 5 × 10
-8
, suggesting insufficient power to reject the null 
hypothesis in genome-wide scan. Recently Chen et al.
167
 reported a meta-analysis GWAS on 
corneal curvature in collaboration with Japanese and Chinese groups. An initial GWAS on corneal 
curvature in the UK samples (the Avon Longitudinal Study of Parents and Children (ALSPAC) was 
also been reported
172
. Combining GWAS outcomes from these studies would be a next step to 
understand the genetic basis of corneal curvature. In addition, replicating the associations in 
keratoconus and myopia samples may help to understand the aetiology of keratoconus and myopia 
diseases respectively. 
Glaucoma is characterised as the irreversible blindness (one or both eyes) due to optic neuropathy. 
Primary Open angle glaucoma (POAG) is the most common type of glaucoma. The clinical 
diagnosis and follow up of POAG patients is based on measurements of VCDR, intraocular 
pressure (IOP), and central corneal thickness (CCT). Individuals diagnosed with POAG are 
phenotypically heterogeneous. For example not all individuals with increased IOP develop POAG 
nor do all POAG patients show high IOP. This complicates the genetic mapping of POAG, as the 
power of case-control GWAS of POAG will be reduced if a heterogeneous population is used in 
which different sets of markers regulate variation in VCDR, IOP and CCT. In chapter 4, we 
demonstrate how an endophenotype approach helps to identify POAG relevant loci (8 of the 18 loci 
associated with VCDR are replicated in POAG samples). Similar studies were performed to identify 
IOP and CCT specific loci conferring POAG risk
79; 173
. Identifying glaucoma-associated locus that 
regulates variation in an endophenotype may help to determine glaucoma risk to a healthy 
individual. Earlier diagnosis of glaucoma may lead to better treatment and protection from 
blindness. For example, if an individual have variants responsible for higher IOP and POAG, IOP 
lowering medication can be used to prevent further nerve damage. Apart from IOP lowering 
medication, no other treatments till date are developed for POAG. Identifying genes associated with 
variation in the endophenotypes may help in development of drugs targeting possible biological 
mechanism(s) behind POAG. VCDR measures the extent of nerve damage in glaucoma patients. 
Genes associated with VCDR will help to understand the biological pathway behind optic 
neuropathy; drugs targeting such pathways can be used for glaucoma treatment. 
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Our GWAS results supports association of the transforming growth factor beta (TGFB) pathway 
with VCDR. The newly associated genes BMP2 belongs to TGFB super-family, RPAP3 and 
CARD10 are involved in regulation of Apoptosis. The TGFB signalling pathway is considered to be 
a central mechanism for neurodegeneration
174-179
. Neuro-inflammation is one of the shared 
characteristics of glaucoma and Alzheimer’s disease180. The accumulation of amyloid-beta peptide 
is important for the pathogenesis of Alzheimer’s disease. The TGFB signalling pathway is involved 
in clearance of amyloid-beta peptide (a neurotoxin) from brain
181
. Recently Yang et al.
182
 reported 
that the cerebrospinal fluid pressure is associated with optic nerve damage. Cerebrospinal fluid is 
involved in clearance of toxins
183
. These recent developments and our results support shared 
molecular mechanism between optic nerve degeneration and neurodegenerative disorders. Further 
validations are needed to establish the cross phenotype associations. Establishing this relationship 
would have several advantages. For example, the VCDR parameter could be used to detect a 
possible neurodegenerative disorder risk in future life. In addition the therapies directed to treat 
neurodegenerative disorders could be used to treat glaucoma. 
In chapter 5 we report that all common SNPs explain 41-53% phenotypic variation in VCDR using 
samples from Rotterdam studies whereas only 5.1-5.9% variation is explained by 18 loci. Our 
heritability estimates for VCDR is aligned with the other evidences suggesting common variants 
explain around 50% of heritability in many complex traits
184
. Recently Yang et al.
185
 reported that 
genotypes from commonly used SNP arrays, namely Affymetrix 6.0, Affymetrix Axiom, Illumina 
OmniExpress and Illumina Omni2.5, imputed to the 1000 Genomes Project reference panels 
captures ˜97% and ˜68% of variation at common and rare variants respectively. Imputing lower 
frequency variants with high effect and increasing sample size might help explaining the heritability 
of VCDR. This directs an obvious next step of experimentation. During the candidature I (under 
supervision of Stuart Macgregor) designed the study to perform the large-scale meta-analyses of 
different POAG endophenotypes (IOP, VCDR, CCT, disc area, cup area and rim area). It included 
meta-analysis of 1000 Genomes phase 1 imputed SNPs, previously unexplored X chromosome and 
mitochondrial genome analysis. These projects will be written up in 2015. 
7.2.3 Application of Post-GWAS methods on corneal astigmatism and VCDR 
I applied VEGAS gene-based test on corneal astigmatism but none of the genes reached the 
significance threshold of 2.80 × 10
-6
 (p-value < 0.05 corrected for the total number of human genes, 
17,872). Then I performed pathway analysis using the VEGAS-Pathway software on gene ontology 
(GO) pathways
121
. The GO:0035282 pathway (GO term: segmentation, p-value = 2.0 × 10
-6
) is 
significantly associated with corneal astigmatism at threshold 1.08 × 10
-5
 (0.05/4,628, corrected for 
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total number of GO pathways tested, 4,628). This analysis highlights the improved power of gene-
set approach over an individual gene association tests (per-SNP GWAS or gene-based test) in 
identification of associated loci with a polygenic phenotype. The genes contained in the 
segmentation pathway are biologically relevant to corneal astigmatism. MSGN1, MEOX1, MEOX2 
and TDGF1 are involved in the differentiation of mesoderm to form mesenchyme, mesothelium and 
coelomocytes
186-188
. During embryogenesis in vertebrates, periocular mesenchymal cells give rise to 
the stroma of cornea. Disturbance of this process may lead to irregular shape of cornea, causing 
corneal astigmatism. Several genes in GO:0035282 are from HOX family (HOXD8, HOXA2, 
HOXB6). In mice, HOX8.1 express during ocular development
189
. Further characterization in 
human tissues is needed to establish the possible role of these genes in the development of eye. 
Chapter 4 reports significant associations between VCDR and two novel genes PITPNB (p-value = 
4.89 × 10
-7
) and REEP5 (p-value = 7.48 × 10
-7
), through the VEGAS gene-based approach. This is a 
good demonstration of joint SNP analysis to identify genes associated with a trait that are non-
significant through a per-SNP approach. Chapter 4 also reports association of GO:0045736 pathway 
(GO term = negative regulation of cyclin-dependent protein kinase activity, p-value = 1.08 × 10
-6
) 
with VCDR through the VEGAS-Pathway approach. The GO:0045736 pathway is an interesting 
pathway for VCDR. Genes contained in this pathway reduces the rate of cyclin-dependent protein 
serine/threonine kinase activity. Cyclin-dependent kinases regulate cell cycle proliferation and 
apoptosis
190; 191
. As mentioned earlier, glaucoma is characterized by the degeneration of retinal 
ganglion cells. GO:0045736 association with VCDR suggests a possible biological mechanism 
behind this retinal ganglion cell death. Pathway analysis also implicates the APC gene. This gene is 
close to REEP5, which was found associated with VCDR using gene-based test. It highlights one of 
the limitations of gene-based approach, that the gene-based results of neighboring genes can be 
ambiguous. Gene-based association test statistics of a gene is calculated based on the SNPs it 
contains. The test for neighboring genes may be calculated by a set of SNPs that are overlapping or 
in high LD (as the case with APC and REEP5, Figure 2), hence an independent association tests of 
neighboring genes may report correlated p-values. Gene-based results should be interpreted with 
consideration of LD structure of the region. We recommend an analyst should provide an 
association plot for the reported genes. In the scenario of APC and REEP5 association with VCDR, 
pathway analysis supported APC gene. APC would be a good candidate for further characterization, 
but SNPs in REEP5 also show significant association. A fine mapping experiment to locate a causal 
variant may help to understand possible genetic architecture. 
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Figure 7.2: Locuszoom plot192 at APC/REEP5 locus using European GWAS data on 
VCDR  
7.2.4 VEGAS2 software for gene-based tests 
In chapter 5, I report the VEGAS2 software as an extension of the VEGAS approach. VEGAS2 
uses the 1000 Genomes reference set to perform gene-based tests on autosomes and the X 
chromosome, and provides greater flexibility in gene boundary selection. As explained in chapter 1, 
the 1000 Genomes resource has several advantages over the HapMap resource. In addition to 99% 
of common variants (MAF > 0.05) provided by the HapMap data, the 1000 Genomes phase 1 
resource includes tens of millions of rare (MAF < 0.05) and common (MAF > 0.05) SNPs. Also the 
1000 Genomes resource contain a larger number of individuals resulting in a more accurate estimate 
of LD. Moreover, SNPs known to be important in different human diseases are absent in HapMap 
reference data
193
; for example rs429358 and rs7412 SNPs that determine three Apolipoprotein E 
(APOE) isoforms (APOE2, APOE3, and APOE4)
194
, an important candidate in various neurological 
and non-neurological disorders including Alzheimer’s disease195-198, cerebral amyloid 
angiopathy
199
, lobar intracerebral haemorrhage
200
 and hiperlipidemia
201
. The only SNP rs80125357 
in high LD with rs7412 in the 1000 Genomes pilot data (r
2
 = 0.881) is also absent in all releases of 
HapMap data. In GWAS summary data where such SNPs are present, for gene-based test the 
VEGAS approach utilising the HapMap data would have ignored them. Hence the VEGAS 
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approach utilising the 1000 Genomes data may reveal additional genes associated with the trait due 
to the greater SNP coverage compared to the HapMap resource. 
As mentioned in chapter 1, the 1000 Genomes data uses both low coverage (4-6x) whole genome 
sequencing approach and high coverage (50-100x) exome sequencing approach to identify variants 
in the human genome. The LD information from HapMap resource, dense genotyping platforms and 
exome sequence data was incorporated to achieve a high accuracy for low coverage variants. The 
high coverage exome sequencing covered the consensus capture target region (across different 
platforms) of 24 Mb spanning over 15,000 genes
25
. The variants neither in LD with variants in 24 
Mb high coverage regions nor with variants in HapMap resource might have been identified with 
less accuracy. This is less likely to affect gene-based test since high coverage exome sequencing 
identified variants in genic regions. 
Traditionally, very few attempts were made to include X chromosome in GWAS. Only 242 out of 
743 (~33%) GWAS published in the period 2005 to 2010 considered the X chromosome
202
. The 
few attempts made have identified variants associated with sex-specific complex traits such as male 
pattern baldness
203; 204
 and prostate cancer
205; 206
, and non-sex-specific complex traits such as 
schizophrenia
207
, height
208; 209
 and rheumatoid arthritis
210
. These findings suggest the importance of 
inclusion of X chromosome in gene mapping of complex traits (both sex-linked and non-sex 
linked). 
The exclusion of the X chromosome from GWAS analysis is attributed to several factors such as 
genotype coverage (the HapMap based genotyping array Illumina HumanOmniExpress-24 assays 
only 17,502 markers in X chromosome), and complications in genotype calling, imputation and 
association tests (due to hemizygous males and dizygous females). Combined efforts from 
genotyping companies and methodology developers make it the most exciting time for inclusion of 
the X chromosome in GWAS designs. The 1000 Genomes and HapMap resource based Illumina 
HumanOmni5 assays 113,213 markers in X chromosome, which provides better variation coverage 
across whole X chromosome. A comparative study by Ritchie et al.
211
 suggests the genotype calling 
algorithms utilizing sex information outperforms methods that ignore gender information to call 
genotypes in X chromosome. Implementations such as IMPUTE2 are developed to impute X 
chromosome variants in samples containing both males and females (it apply similar algorithm as 
that on autosome while considering the gender information and adjusting for effective population 
size by reducing Ne parameter to 3/4
th
 that for autosomes)
212; 213
. Different association test models 
(sex stratified models where males and females are analysed separately, and X-inactivation model
89
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a combined analysis where males are treated as homozygous females) for X chromosome analysis 
suits different scenarios. For example, separate analysis on male and female samples may be 
suitable to identify sex-linked variants associated with a trait but it may reduce the effective sample 
size if case and control status is highly imbalanced e.g. an extreme example where all cases are 
male and controls are female. In the case of such an imbalance the X-inactivation model will be 
more powerful)
214
. Popular association test software such as PLINK 1.90
93
 and SNPTEST
215
 
provide implementations of different statistical strategies for X chromosome single marker 
association tests. The VEGAS2 implementation of a gene-based test suitable for the X chromosome 
fits perfectly with the current pace of development of X chromosome analysis. 
Recently Gusev et al.
216
 reported that on average 79% of the heritability of 11 common diseases is 
explained by variants in DNaseI hypersensitivity sites (an accessible region of DNA for cleavage by 
DNase I enzyme, these open chromatin regions are where the regulatory proteins bind to monitor 
the transcription rate) whereas 21% is explained by variants in coding regions (11% by common 
variants and 10% by rare variants).  In the VEGAS2 software we gave users flexibility in the choice 
of the gene boundary. It will allow user to decide either to include the variants farther away from a 
gene or to reduce the number to tested SNPs by considering only variants in coding region and/or 
include variants in untranslated regions. In future, most of the open chromatin region defined by 
sensitivity to DNaseI cleavage, for example as reported by ENCODE (Encyclopaedia of DNA 
elements)
217
, can be incorporated into VEGAS2. However, assignment of a specific region of open 
chromatin region to a given gene is complicated by our imperfect gene regulatory knowledge. 
Recently several analyses reported on expression quantitative trait loci (eQTL), which are variants 
associated with variation in the expression of a gene
218-221
. The eQTLs can be used to identify open 
chromatin regions associated with a gene. For example, if a SNP that is an eQTL falls in an open 
chromatin region, it is likely that region is a binding site for the regulator of that particular gene. 
This is a possible future improvement for VEGAS2, which would allow for more powerful gene-
based tests. 
Traditionally, GWAS approaches have concentrated on the analysis of common variants because 
most variants typed on commercial genotyping arrays are common. As noted in chapter 1, for 
quantitative traits about half of the heritability is accounted for by common variants
32; 222
. For 
disease traits Lee et al.
223
 found that common variants explain one third to half of the heritability. 
More recent reports using a different method suggest the proportion of the variance in selected 
disease phenotypes accounted for by common variants is higher still (~60%)
224
. The question is 
hence, for the remaining heritability, is this accounted for by rare variants? 
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It is useful to consider how one might assay rare variation. Mägi et al.
225
 used imputation to infer 
rare variants from common variant chip data. They reported association of rare variants in PRDM10 
with coronary artery disease and several genes in major histocompatibility complex with type-1 
diabetes. Imputation infers the genotype of a variant based on the LD with the genotyped SNPs in 
the reference panel, which is the function of allele frequency. The accuracy of imputation decreases 
proportionally to a SNPs’ minor allele frequency226. Also the performance of imputation scales with 
the size of the reference panel and the density of the input genotyping array
227
. The availability of 
the larger reference panels will help in assaying rare variants with high accuracy using imputation. 
Furthermore, exome chips from commercial venders such as Affymetrix and Illumina allow one to 
assay rare variants directly. These arrays were developed using 12,000 sequenced exomes as a 
reference, mostly of European ancestry
226
. Due to their relatively low cost compared to sequencing 
approaches, exome chips can be used to genotype a large number of individuals resulting in better-
powered association tests for rare variants. Through exome chip genotyping 8,229 non-diabetic 
finish males Huyghe et al.
228
 reported association of low frequency variants in SGM2 and MADD 
with insulin processing and secretion. Recently Wessel et al.
229
 reported the association of a low 
frequency non-synonymous variant in GLP1R with fasting glucose by exome chip genotyping 
60,564 non-diabetic individuals. Although there have been a few successes, association tests based 
on exome chip data have several limitations. Firstly, the 12,000 sequenced exomes used for the 
development of exome chips were of European decent, hence rare variants in other ancestries that 
are monomorphic in the Europeans are underrepresented
230
. Another limitation of exome chips (and 
array based technology in general) is that they can successfully genotype only those variants 
flanked by short unique sequences containing an appropriate proportion of guanine and cytosine 
bases
226
. These limitations can be overcome using sequencing technology (e.g. exome sequencing, 
targeted sequencing or whole genome sequencing). 
Sequencing technology allows one to assay all variants within a part of or across the whole genome 
in an individual. Hence sequence data will help in understanding what proportion of the remaining 
missing heritability is due to rare variants. The alleles strongly predisposing to a disease are likely 
to be kept at low frequency in a population due to purifying selection
231-233
. Such low frequency 
variants with large effects on a disease can further be used as targets for clinical intervention. 
Recently, Do et al.
234
 identified a rare nonsynonymous mutation in LDLR that explains 0.48% of 
the heritability of early onset myocardial infarction by exome sequencing 9,793 myocardial 
infarction patients and controls. Targeted gene sequencing has identified missense mutations in 
PCSK9 associated with low plasma low-density lipoprotein cholesterol and a protective effect 
against coronary heart disease
235; 236
. However, as mentioned earlier, Gusev et al.
216
 reported that 
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non-coding regulatory regions marked by DNaseI hypersensitivity sites harbor a large proportion of 
complex trait heritability. Since exome-sequencing and targeted gene sequencing are limited to 
coding regions, they might not be helpful in revealing the full genetic architecture of complex 
diseases. The continuing reductions in the cost of whole genome sequencing will make it possible to 
perform genome-wide association analysis of both common and rare variants genome-wide. 
Statistical intervention will be required to control for false positive findings, since the traditional 
genome-wide significance threshold of 5 × 10
-8
, which was derived using HapMap data for 
common variant GWAS
46; 47
, might not remain relevant. 
The power of an association tests depends on the allele frequency and the effect size. At the same 
effect size for a single variant, the association test statistic of a common variant would be more 
significant than that of a rare variant. The power of rare variant association test can be improved by 
aggregating the effects of all individual variants in a gene. Burden tests and sequence kernel 
association tests (SKAT) are some of the most popular algorithms developed to combine test 
statistics of rare-variants. Burden tests create a burden variable for a gene by collapsing all rare 
variants in it
237-242
. Instead of collapsing variants, SKAT computes a weighted sum of squares of 
individual variant test statistics
243
. The fundamental difference between these approaches and 
VEGAS2 is that the rare-variant gene-based approaches generally discard common variants 
(because otherwise the result for any rare variants would be swamped by the result at common 
variants) whereas VEGAS2 discards rare variants. So at present rare variant and common variant 
gene-based approaches (such as VEGAS2) are complementary to each other. With appropriate 
testing and evaluation the current implementation of VEGAS2 can be extended to perform gene-
based test using both rare and common variants. But in this framework the effect size at rare variant 
need to be stronger to overcome the association signal observed at common variants. 
Inclusion of non-risk variants could lead to a conservative gene-based test. Prioritising variants 
based on their functional relevance has been proposed to reduce noise in gene-based approaches
226; 
233
. Zuk et al.
233
 proposed to use only disruptive variants in gene-based analysis of rare variants. 
The difference in allele frequency between cases and controls aggregated over all disruptive 
variants would reflect the overall effect of rare mutations in a gene onto a phenotype. In the future 
this association test statistic of rare variants could be combined with the aggregated test statistic of 
common variants in the VEGAS2 framework to compute a gene-based association p-value. Other 
rare variants (non-disruptive variants) might also be included in the analysis without diluting the 
aggregated gene-based test statistics. For example, missense alleles might play an important role in 
variation of complex phenotypes. Bioinformatics tools such as SIFT
244; 245
 and Polyphen-2
246
 can be 
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used to distinguish damaging missense variants from benign ones. These damaging missense 
variants can be used in gene-based analysis. As our understanding of the regulatory regions 
improves, rare variants in these regions could potentially also be included in gene-based analysis. 
7.2.5 VEGAS2Pathway - a pathway analysis approach for GWAS summary 
data 
In chapter 3 and chapter 4 we reported the advantages of pathway analysis on GWAS summary data 
to identify possible biological mechanisms behind the variation in corneal astigmatism and VCDR 
respectively. We used VEGAS-Pathway package (an under development method). This method 
does not account for all the issues related to pathway analysis of GWAS data (mentioned in chapter 
1). For example, if a pathway contains number of neighbouring genes in it, then VEGAS-Pathway 
(like MAGENTA
117
, mentioned in chapter 1 and chapter 6) keeps only one out of all neighbouring 
genes to calculate pathway test statistic. In chapter 6, we discuss how VEGAS2Pathway approach 
address several issues related to pathway analysis of GWAS data, which most of the pathway 
approaches failed to account. Here I am discussing possible future improvements in 
VEGAS2Pathway approach. 
The implementation of VEGAS2Pathway approach discussed in chapter 6, used curated and GO 
pathways from MSigDB 
120
 database. MSigDB filters GO pathways with less than 10 genes while 
ignoring the hierarchical structure. For example, the MALE_GONAD_DEVELOPMENT pathway 
in MSigDB contains 12 genes of GO:0008584, but genes from its child terms (pathways that are 
part of a pathway one step above in the hierarchy) GO:0033327, GO:0060008, GO:0060011 and 
GO:0072520 are ignored. Using GO pathways from MSigDB database is one of the limitations of 
this thesis, since very few GO pathways were present for analysis (1454) and many important genes 
(from child terms) were absent in those pathways. In future VEGAS2Pathway implementation, in 
addition to the curated pathways we will use the nested GO pathways (such that genes in all child 
terms are present in a parent term). In this way, the genomic coverage for pathway analysis will be 
improved. 
MSigDB contains both manually curated (from databases such as KEGG 
122
, BIOCARTA and 
REACTOME 
247
), and computationally predicted pathways (from GO database). We find the 
pathways from these databases do not match. For example, only 31 genes overlap between 
REACTOME_APOPTOSIS [148] and KEGG_APOPTOSIS [88], only 44 genes overlap between 
APOPTOSIS_GO [431] and REACTOME_APOPTOSIS [148], and only 37 between 
APOPTOSIS_GO [431] and KEGG_APOPTOSIS [88] in MSigDB database. Different databases 
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use different algorithms to assign genes to a pathway. Pathway annotations in the curated databases 
are based on the research publication (in some databases it is easy to find references for each 
annotations (REACTOME) and others it is difficult to track (KEGG)), whereas computationally 
predicted annotations are typically based on sequence or structural homology. All these annotations 
(both curated and computationally predicted) are biologically relevant. Arguably a pathway 
containing genes annotated to a specific process in at least one of the standard database would be a 
better representative for pathway analysis of GWAS data. This would improve power of association 
test since association test statistics of all possible genes involved in a particular biological 
mechanism would be used. The other side of argument is that the annotations in different databases 
is based on different sets of evidences of interactions hence a nested pathway across different 
databases may not report a specific molecular mechanism. But such nesting may help to identify 
possibly new interactions. 
The future improvements in VEGAS2 (such as inclusion of variants in open reading frame, eQTL 
and rare variants, refer previous section) can be extended to VEGAS2Pathway. The improved gene-
based test statistics will lead to better-powered pathway association test. 
Pathway analyses of GWAS data have several advantages but the results should be interpreted 
carefully. In a pathway analysis publication the genes and in turn SNPs driving the association tests 
statistics must be reported. This allows reader to make better judgement of an association for further 
characterisation. A pathway test statistics can be driven by a single genome-wide significant SNP, 
but such results may not be very interesting. If many genes drive a pathway, such findings would 
explain possible biological mechanisms for drug target. Such findings will also help to identify 
additional genes for further characterisation (for example the APC gene identified through pathway 
analysis for VCDR). 
7.3 Concluding remarks 
The replication report in chapter 2 and chapter 3 helped in validation of previously reported 
association. The report of initial GWAS opened the scope for further collaboration for large-scale 
cross ancestry meta-analysis of corneal curvature and corneal astigmatism. Under consortium of 
refractive error and myopia (CREAM) different groups participated in a cross ancestry meta-
analysis of astigmatism
248
. A large-scale meta-analysis on corneal curvature is also being 
conducted. The large scale-analysis will improve our understanding of the genetic basis of these 
complex traits. 
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In chapter 4, the 18 loci (10 novel findings) associated with VCDR suggest involvement of the 
TGFB signalling pathway in optic nerve degeneration. This pathway is a candidate for several 
neurodegenerative disorders. The GWAS analysis on VCDR develops a new hypothesis suggesting 
possible genetic overlap between neurodegenerative disorders and optic nerve degeneration. Further 
we replicated 8 of the 18 loci associated with VCDR in POAG samples. The risk score analysis in 
Caucasian samples suggests the individuals in highest quintile have 2.5-fold increased risk of 
POAG than the individuals in the lowest quintile. This is a good demonstration of application of an 
endophenotype approach to identify disease risk loci. 
Chapter 4 also demonstrates the application of gene-based and pathway-based approaches. We 
identified two novel loci associated with VCDR using the gene-based approach, which were non-
significant in single marker GWAS analysis. This finding supports the use of gene-based methods 
as a complement to the single marker GWAS. The significantly associated pathway GO:0045736 
(GO term = negative regulation of cyclin-dependent protein kinase activity) suggests cell death. 
This pathway is likely to be involved in the retinal ganglion cell death. CDKN2A and APC genes 
drive this pathway, which could be possible targets for glaucoma treatment. 
In chapter 5, I report the VEGAS2 software for gene-based test of GWAS summary data. It will 
allow users to leverage the increased coverage of the 1000 Genomes data and expand their analysis 
to include the X chromosome for gene-based association tests. Finally, I provide the 
VEGAS2Pathway approach for pathway analysis of GWAS data. I demonstrated how this approach 
accounts for different confounders that may bias the pathway association results. Overall this thesis 
significantly contributes to ophthalmology research and genetic epidemiology research at large by 
providing platforms for gene-based and pathway-based tests, which may help in identifying novel 
loci and understanding biological mechanisms behind the variation in human traits. 
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